Fredericamycin derivatives

ABSTRACT

The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases.

The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, particularly cancer diseases.

Fredericamycin has been isolated 1981 from Streptomyces griseus, and demonstrates anti- cancer activity.

Fredericamycin and several fredericamycin derivatives are known.

In Heterocycles 37 (1994) 1893-1912, J. Am. Chem. Soc. 116 (1994) 9921-9926, J. Am. Chem. Soc. 116 (1994) 11275-11286, J. Am. Chem. Soc. 117 (1995) 11839-11849, JP 2000-072752, and in J. Am. Chem. Soc. 123 (2001), various total syntheses of fredericamycin A have been described, some being enantio-selective.

In U.S. Pat. No. 4,673,768, alkali salts of the fredericamycin A are described. In U.S. Pat. No. 4,584,377, fredericamycin derivatives are described, particularly derivatives acylated in ring E and F. In U.S. Pat. No. 5,166,208, fredericamycin derivatives are described as well, particularly derivatives carrying thio and amino substituents in ring F. The derivatives are generated semi- synthetically or fully synthetically.

Surprisingly it was found that fredericamycin derivatives, especially those derivatized in ring A, represent potent drugs. Also, a possibility was found to introduce such residues in ring A semi-synthetically, with which the water solubility and/or the biological effect, the spectrum of action in comparison with fredericamycin, can be significantly increased. Furthermore, an alternative method was found to make fredericamycin and its derivatives water-soluble by generating cyclodextrin inclusion compounds.

The invention relates to novel fredericamycin derivatives with the general Formula Ia or Ib:

wherein in each,

-   R1 means H, C₁-C₆ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, -   R2 means H, C₁-C₁₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl,     heteroaryl, C₁-C₄ alkyl heteroaryl, C₂-C₄ alkenylheteroaryl,     cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄     alkylheterocycloalkyl, C_(m)H_(2m+o−p−p)Y_(p) (with m=1 to 6, for     o=1, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6,     o=−2, p=1 to 2 m+o; Y=independently selected from the group     consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21),     (CH₂)_(r)CH₂NHCOR21, (CH₂)_(r)CH₂OCOR21, (CH₂)_(r)CH₂NHCSR21,     (CH₂)_(r)CH₂S(O)nR21, with n=0, 1, 2, (CH₂)_(r)CH₂SCOR21,     (CH₂)_(r)CH₂OSO₂—R21, (CH₂)_(r)CHO, (CH₂)_(r)CH═NOH,     (CH₂)_(r)CH(OH)R21, —(CH₂)_(r)CH═NOR21, (CH₂)_(r)CH═NOCOR21,     (CH₂)_(r)CH═NOCH₂CONR21R22, (CH₂)_(r)CH═NOCH(CH₃)CONR21R22,     —(CH₂)_(r)CH═NOC(CH₃)₂CONR21R22, (CH₂)_(r)CH═N—NHCO—R23,     (CH₂)_(r)CH═N—NHC(O)NH—R23, (CH₂)_(r)CH═N—NHC(S)NH—R23,     (CH₂)_(r)CH═N—NHC(NH)NH—R23, (CH₂)_(r)CH═N—NHC(NH)—R23,     (CH₂)_(r)CH═N—NHCO—CH₂NHCOR21, (CH₂)_(r)CH═N—O—CH₂NHCOR21,     (CH₂)_(r)CH═N—NHCS—R23, (CH₂)_(r)CH═CR24R25 (trans or cis),     (CH₂)_(r)COOH, (CH₂)_(r)COOR21, (CH₂)_(r)CONR21R22,     —(CH₂)_(r)CH═NR21, (CH₂)_(r)CH═N—NR21R22,     and the (CH₂)_(r)-chain elongated residue     (CH₂)_(r)CH═N—N—(C₃NX′R211R212R213R214) (with X′=NR215, O, S, and     R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl),     —(CH₂)_(r)CH═N—NHSO₂ aryl, —(CH₂)_(r)CH═N—NHSO₂ heteroaryl, with     r=0, 1, 2, 3, 4, 5, preferably 0, -   R21, R22 are independently H, C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆     alkylhydroxy, C₁-C₆ alkoxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆     alkyl, C₁-C₆ alkylamino-di-C₁-C₆ alkyl, cycloalkyl, C₁-C₄     alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl,     aryl, aryloyl, C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄     alkylheteroaryl, cycloalkanoyl, C₁- C₄ alkanoylcycloalkyl,     heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄     alkanoylaryl, C₁-C₄ alkanoylheteroaryl, mono- and di-sugar residues     linked through a C atom which would carry an OH residue in the     sugar, wherein the sugars are independently selected from the group     consisting of glucuronic acid and its stereo isomers at all optical     atoms, aldopentoses, aldohexoses, including their desoxy compounds     (as e.g. glucose, desoxyglucose, ribose, desoxyribose), or R21 and     R22, together with the N, form a ring with 4, 5, 6, 7, or 8 members,     which may optionally contain still another heteroatom selected from     the group N, O, S, -   R23 independently of R21, has the same meanings as R21, or     CH₂-pyridinium salts, CH₂-tri-C₁-C₆ alkylammonium salts, CONH₂,     CSNH₂, CN, CH₂CN, -   R24 independently of R21, has the same meanings as R21, or H, CN,     COCH₃, COOH, COOR21, CONR21R22, NH₂, NHCOR21, -   R25 independently of R21, has the same meanings as R21, or H, CN,     COCH₃, COOH, COOR21, CONR21R22, NH₂, NHCOR21, -   R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8     members, which may optionally contain still another heteroatom     selected from the group N, O, S, -   R3 means H, F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO,     NHCOR31, NHCOCF₃, CH_(3-m)hal_(m) (with hal=Cl, F, particularly F,     and m=1, 2, 3), OCOR31, -   R31, R32 are independently C₁-C₆ alkyl, or R31 and R32, together     with the N, form a ring with 4, 5, 6, 7, or 8 members, which may     optionally contain still another heteroatom selected from the group     N, O, S, -   R5 means H, C₁-C₂₀ alkyl, cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₁₀     alkinyl, C₁-C₄ alkyl cycloalkyl, heterocycloalkyl, C₁-C₄ alkyl     heterocycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄     alkylheteroaryl, C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1     to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1     to 2 m+o; Y=independently selected from the group consisting of     halogen, OH, OR51, NH₂, NHR51, NR51R52, SH, SR21),     (CH₂)_(s)CH₂NHCOR51, (CH₂),CH₂NHCSR51, (CH₂),CH₂S(O)_(n)R51, with     n=0, 1, 2, (CH₂)_(s)CH₂SCOR51, (CH₂),CH₂OCOR51,     (CH₂)_(s)CH₂OSO₂—R51, (CH₂)_(s)CH(OH)R51, (CH₂),COOH, (CH₂),COOR51,     (CH₂),CONR51R52, with s=0, 1, 2, 3, 4, 5, preferably 0, mono- and     di-sugar residues linked through a C atom which would carry an OH     residue in the sugar, wherein the sugars are independently selected     from the group consisting of glucuronic acid and its stereo isomers     at all optical atoms, aldopentoses, aldohexoses, including their     desoxy compounds (as e.g. glucose, desoxyglucose, ribose,     desoxyribose), with the mono- sugar residues such as aldopentoses,     aldohexoses, including their desoxy compounds (as e.g. glucose,     desoxyglucose, ribose, desoxyribose) being preferred, with R51, R52     which are capable of independently adopting the meaning of R21, R22, -   R4, R6, R7 independently mean H, C₁-C₆ alkyl, CO—R41, -   R41 independently from R21, has the same meanings as R21, -   X means O, S, NH, N—R8, wherein R8 independently from R5 may adopt     the same meaning as R5, or R5 and R8, together with the N, form a     ring with 4, 5, 6, 7, or 8 members, which may optionally contain     still another heteroatom selected from the group N, O, S, -   or X—R5 may together be H, -   Y means O, S, NR9, wherein R9 may be H or C₁-C₆ alkyl,     as well their stereoisomers, tautomers, and their physiologically     tolerable salts or inclusion compounds, wherein the residues for     Formula Ia may not concomitantly adopt the following meaning, except     in case of cyclodextrin inclusion compounds: R1: H, C₁-C₆ alkyl, R2:     C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and     independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl,     aryl, and R7 being H, C₁-C₆ alkyl, Y: 0, and for Formula Ib: R1: H,     R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6     being H, and X—R5 being methoxy, Y: O. Preferably, the substituents     do not concomitantly adopt the following meaning: R1, R3: H, R2: H,     alkyl, hydroxyalkyl, particularly monohydroxyalkyl, alkoxyalkyl,     CF₃, (CH₂)_(r)COOH, CHO, CONH₂, (CH₂)_(r)CH₂NHCO alkyl,     (CH₂)_(r)CH₂OCO alkyl, (CH₂)_(r)CH₂NHCS alkyl, CH═NOH, CH═NO alkyl,     aryl, alkylaryl, alkylheteroaryl, alkenyl, hydroxyalkenyl,     particularly monohydroxyalkenyl, R4, R6, R7: H, alkyl, X—R5: H, R5:     H, alkyl, aryl.

Preferred are compounds of Formula IIa or IIb

wherein the meaning of the residues R1-R41, X is as described above, their tautomers and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula Ia may not concomitantly adopt the following meaning, except in the case of cyclodextrin inclusion compounds: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, Y: O, and for Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X—R5 being methoxy, Y: O.

The invention further relates to compounds of Formula Ia, Ib, IIa or IIb, in which the residues R, except for R2, have the above described meanings, and the water solubility of R2 is at least two times higher, preferably at least five timer higher, more preferred at least ten times higher, especially preferred at least fifty time higher, particularly one hundred times higher, or even five hundred times higher than of R2 being CH═CH—CH═CH—CH₃, when all other residues are maintained. The increase in the water solubility is achieved e.g. by introduction of groups which can form additional hydrogen bonds, and/or are polar, and/or are ionic. A key intermediate are compounds with an aldehyde function in R2.

For R2 preferred is also the group of the residues C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o; Y=independently selected from the group of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21), (CH₂)_(r)CH₂NHCOR21, (CH₂)_(r)CH₂OCOR21, (CH₂)_(r)CH₂NHCSR21, (CH₂)_(r)CH₂S(O)_(n)R21, with n=0, 1, 2, (CH₂)_(r)CH₂SCOR21, (CH₂)_(r)CH₂OSO₂—R21, (CH₂)_(r)CH(OH)R21, (CH₂)_(r)COOH, (CH₂)_(r)COOR21, (CH₂)_(r)CONR21R22. Still particularly preferred is the group of the aldehyde-derived residues (CH₂)_(r)CHO, (CH₂)_(r)CH═NOH, —(CH₂)_(r)CH═NOR21, (CH₂)_(r)CH═NOCOR21, (CH₂)_(r)CH═NOCH₂CONR21R22, (CH₂)_(r)CH═N—NHCO—R23, (CH₂)_(r)CH═N—NHC(O)NH—R23, (CH₂)_(r)CH═N—NHC(S)NH—R23, (CH₂)_(r)CH═N—NHC(NH)NH—R23, (CH₂)_(r)CH═N—NHC(NH)—R23, (CH₂)_(r)CH═N—NHCO—CH₂NHCOR21, (CH₂)_(r)CH═N—O—CH₂NHCOR21, (CH₂)_(r)CH═N—NHCS—R23, (CH₂)_(r)CH═CR24R25 (trans or cis), (CH₂)_(r)CH═NR21, (CH₂)_(r)CH═N—NR21R22,

and the (CH₂)_(r)-chain elongated residue (CH₂)_(r)CH═N—N—(C₃NX′R211R212R213R214) (with X′=NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl), —(CH₂)_(r)CH═N—NHSO₂ aryl, (CH₂)_(r)CH═N—NHSO₂ heteroaryl, (CH₂)_(r)CH═CH heteroaryl, with r=0, 1, 2, 3, 4, 5, preferably 0.

From the aldehydes and thereof derived compounds, such are preferred in which at least R1 or r3 are not H, if R4 to R7 are H or alkyl.

Preferred residues in R2 are further heteroaryl, cycloaryl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkyl heterocycloalkyl, C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o; Y=independently selected from the group of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21), CH₂NHCOR21, CH₂NHCSR21, CH₂S(O)_(n)R21, with n=0, 1, 2, CH₂SCOR21, CH₂OSO₂—R21, CH(OH)R21, CH═NOCOR21, —CH═NOCH₂CONR21R22, —CH═NOCH(CH₃)—CONR21R22, CH═NOC(CH₃)₂CONR11R22, CH═N—NHCO—R23, —CH═N—NHCO—CH₂NHCOR21, CH═N—O—CH₂NHCOR21, —CH═N—NHCS—R23, CH═CR24R25 (trans or cis), CONR21R22, —CH═NR21, —CH═N—NR21R22,

(with X′=NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl), CH═N—NHSO₂ aryl, H═N—NHSO₂ heteroaryl.

Furthermore, compounds as described above are preferred, in which R3 means F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH_(3-m)hal_(m) (with hal=Cl, F, particularly F, and m=1, 2, 3), OCOR31, with the above described meanings for R31, R32.

Also preferred are compounds as described above, in which X means N or S, especially when R3 is H or halogen, and/or R2 is alkenyl, particularly butadienyl or 1,3-pentdienyl.

Also preferred are compounds as described above, in which X—R5 is OH, and particularly their salts, and preferred in compounds of Formula Ia or Ia, since this acidic OH group may easily be deprotonized, which increases the water solubility and/or the biological efficacy. Furthermore preferred are still compounds as described above, wherein the residues R preferably independently adopt one or more of the following meanings:

-   R1 means H, C₁-C₅ alkyl, cycloalkyl, especially H, -   R2 means C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl,     C₁-C₄ alkylheteroaryl, C₂-C₄ alkenylheteraryl, CHF₂, CF₃, polyol     side chain, particularly CHOH—CHOH—CHOH—CHOH—CH₃,     CHOH—CHOH—CH═CH—CH₃, CH═CH—CHOH—CHOH—CH₃, CH₂Y (Y═F, Cl, Br, I),     CH₂NH₂, CH₂NR21R22, CH₂NHCOR23, CH₂NHCSR23, CH₂SH; CH₂S(O)_(n)R21,     with n=0, 1, 2, CH₂SCOR21, particularly CH₂OH, CH₂OR21, CH₂OSO₂—R21,     particularly CHO, CH(OR21)₂, CH(SR21)₂, CN, CH═NOH, CH═NOR21,     CH═NOCOR21, CH═N—NHCO—R32, CH═CR24, R25 (trans or cis), particularly     COOH (particularly their physiologically tolerable salts), COOR21,     CONR21R22, —CH═NR21, —CH═N—NR21R22,     (with X′=NR215, O, S, and R211, R212, R213, R214, R215 being     independently H or C₁-C₆ alkyl), —CH═N—NHSO₂ aryl, —CH═N—NHSO₂     heteroaryl, CH═N—NHCO—R23, -   R21, R22 independently mean C₁-C₆ alkyl, cycloalkyl, aryl, C₁-C₄     alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, -   R23 independently of R21, has the same meanings as R21, or     CH₂-pyridinium salts, CH₂-tri-C₁-C₆ alkylammonium salts, -   R24 independently of R21, has the same meanings as R21, or H, CN,     COCH₃, COOH, COOR21, CONR21R22, NH₂, NHCOR21, -   R25 independently of R21, has the same meanings as R21, or H, CN,     COCH₃, COOH, COOR21, CONR21R22, NH₂, NHCOR21, -   R24, R25 together mean C₄-C₈ cycloalkyl, -   R3 means F, Cl, Br, I, NO₂, NH₂, NHCOR31, -   R31 independently means C₁-C₆ alkyl, -   R5 means H, C₁-C₆ alkyl, particularly C₁-C₃ alkyl, C₃-C₈ cycloalkyl,     C₃-C₈ cycloalkenyl, C₁-C₆ alkenyl, C₁-C₆ alkinyls, C₁-C₄     alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl,     aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl,     C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1 to 2 m+o; for m=2     to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o;     Y=independently selected from the group consisting of halogen, OH,     OR21, NH₂, NHR21, NR21R22, SH, SR21), particularly preferred is     hydroxyalkyl with one or more OH groups, -   R4, R6, R7 independently means H, C₁-C₅ alkyl, CO—R41, -   R41 independently from R21, has the same meanings as R21, -   X means O, S, NH, N—R8, -   Y means O, S, NH,     as well their stereoisomers, tautomers, and their physiologically     tolerable salts or inclusion compounds, wherein the residues for     Formula Ia may not concomitantly adopt the following meaning, except     in case of cyclodextrin inclusion compounds: R1: H, C₁-C₆ alkyl, R2:     C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 are identical, and     independently are H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆     alkyl, aryl, and R7 being H, C₁-C₆ alkyl, and for Formula Ib: R1: H,     R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6     being H, and X—R5 being methoxy. -   O, S, particularly O, are preferred for Y. -   O, NH, N—R8 are preferred for X. -   H, methyl, ethyl, propyl, particularly methyl, are preferred for R5. -   H, methyl, ethyl, propyl, particularly methyl, are preferred for R8. -   OCH₃, NH₂, N(CH₃)₂ are preferred for XR5.

For R2 also preferred is the residue —CHOHCHOHCHOHCHOHCH₃.

Furthermore, the following residues are preferred for R2: —CHCH-2-methyl-4-thiazyl, particularly

wherein R particularly is alkyl or NHCO alkyl, CH═NOR21, with R21 being methyl, ethyl, n-propyl, isopropyl, n-butyl, n-hexyl, benzyl, halogen benzyl, particularly fluorobenzyl and chlorobenzyl, —CH₂CH₂ morpholinyl.

Especially preferred are the compounds, the stereo isomers, tautomers, and physiologically tolerable salts or inclusion compounds of which, selected from the group consisting of the compounds of the examples and the compounds, demonstrate combinations of the various substituents of the examples.

Particularly preferred for R3 is H, F, Cl, Br, J, particularly F, Cl, Br, J.

Particularly preferred for R2 is C₁-C₈ alkyl, C₂-C₈ alkenyl, CH═NOR1, with R21 being C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl or heteroaryl, C₁-C₂ alkylaryl, particularly benzyl, C₁-C₂ alkylheteroaryl, wherein aryl or heteroaryl in particular have only one ring system which may be substituted once or twice with a substituent such as halogen, methyl, CF₃, OH, OMe.

Particularly preferred are derivatives of fredericamycin A in which only the above indicated, particularly preferred meanings of R2 and/or R3 are realized.

The invention furthermore relates to drugs containing the above compounds of Formula I or II together with the usual carriers and adjuvants.

Also preferred are the above mentioned drugs in combination with other agents for cancer treatment.

These compounds according to the invention are used for preparation of drugs for treatment of cancers, particularly such that may be treated by inhibition of the topoisomerases I and/or II. Cancers that can be treated with the substances according to the invention are e.g. leukemia, lung cancer, melanomas, uterus tumors, prostate tumors and colon tumors.

Also, fredericamycin A and its derivatives act against an unknown target in the cell cycle leading to apoptosis in tumor cells. Furthermore, the compounds according to the invention, and compounds which have concomitantly adopted the following meanings in Formula Ia: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identically and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, and in Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H and X—R5 being methoxy, are used for preparation of drugs for treatment of neurodermitis, parasites and for immunosuppression.

The invention also relates to a method for preparation of fredericamycin derivatives in which R2 as intermediate is —CHOHCHOHCHOHCHOHCH₃. These compounds are preferably transformed into aldehydes for further derivatization.

In the description and the claims, the substituents are described by the following definitions:

The term “alkyl” by itself or as part of another substituent means a linear or branched alkyl chain radical of the respectively indicated length, in which optionally a CH₂ group may be substituted by a carbonyl function. Thus, C₁₋₄ alkyl may be methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl, C₁₋₆ alkyl, e.g. C₁₋₄ alkyl, pentyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexyl, 3-hexyl, 4-methyl-1-pentyl, or 3,3-dimethylbutyl.

The term “C₁-C₆ alkylhydroxy” by itself or as part of another substituent means a linear or branched alkyl chain radical of the respectively indicated length which may be saturated or unsaturated, and which carries an OH group, e.g. hydroxymethyl, hydroxymethyl, 1-hydroxypropyl, 2-hydroxypropyl.

The term “alkenyl” by itself or as part of another substituent means a linear or branched alkyl chain radical with one or more C═C double bonds of the respectively indicated length, several double bonds being preferably conjugated. Thus, C₂₋₆ alkenyl may for example be ethenyl, 1-propenyl, 2-propenyl, 2-methyl-2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 1,3-butdienyl, 2,4-butdienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1,3-pentdienyl, 2,4-pentdienyl, 1,4-pentdienyl, 1-hexenyl, 2-hexenyl, 1,3-hediexyl, 4-methyl-1-pentenyl, or 3,3-dimethylbutenyl.

The term “alkinyl” by itself or as part of another substituent means a linear or branched alkyl chain radical with one or more C—C triple bonds of the respectively indicated length. Thus, C₂₋ ₆ alkinyl may for example be ethinyl, 1-propinyl, 2-propinyl, 2-methyl-2-propinyl, 2-methyl-1-propinyl, 1-butinyl, 2-butinyl, 1,3-butdiinyl, 2,4-butdiinyl, 1-pentinyl, 2-pentinyl, 3-pentinyl, 1-hexinyl, 2-hexinyl, 4-methyl-1-pentinyl, or 3,3-dimethylbutinyl.

The term “halogen” stands for fluorine, chlorine, bromine, iodine, preferably bromine and chlorine.

The term “NR21R22” preferably stands for a dialkylamino group, wherein the two alkyl groups together with the N can form a ring with 5 or 6 members with optionally one more heteroatom N or O.

The term “cycloalkyl” by itself or as part of another Substituent comprises unsaturated (mono or poly, preferably mono) or saturated, cyclic carbohydrate groups with 3 to 10 C atoms, preferably 3 to 8 C atoms, such as e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohex-2,4-dienyl, 4-methylcyclohexyl, 3-methylcyclohexyl, cycloheptyl or cyclooctyl. Saturated cycloalkyls are preferred. The cycloalkyls may be substituted with up to 3 substituents, preferably with up to 1 substituent, wherein the substituents independently can have the meaning C₁-C₆ alkyl, OH, NO₂, CN, CF₃, OR11, SH, SR11, C₁-C₆ alkylhydroxy, C₁-C₆ alkyl-OR11, COOH, COOR11, NH₂, NHR11, NR11R12, halogen, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ heteroalkylaryl, wherein the residues R11 und R12 independently can mean C₁-C₁₀ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl.

The term “heterocycloalkyl” by itself or as part of another substituent includes cycloalkyl groups, wherein up to two CH₂ groups may be substituted by oxygen, sulfur or nitrogen atoms, and one or two other CH₂ groups may be substituted by one or two carbonyl function(s), carbothionyl function(s), or a carbonyl function and a carbothionyl function, for example pyrrolidine, piperidine, morpholine or

The heterocycloalkyls may be substituted as with the cycloalkyls.

The term “aryl” by itself or as part of another substituent includes aromatic ring systems with up to 3 rings, in which at least 1 ring system is aromatic, and those with up to 3 substituents, preferably up to 1 substituent, wherein the substituents independently can have the meaning C₁-C₆ alkyl, OH, NO₂, CN, CF₃, OR11, SH, SR11, C₁-C₆ alkylhydroxy, C₁-C₆ alkyl-OR11, COOH, COOR11, NH₂, NHR11, NR11R12, halogen, wherein the residues R11 und R12 independently can mean C₁-C₁₀ alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, or R11 and R12, together with the N, form a ring with 4, 5, 6, 7 or 8 members optionally containing still another heteroatom selected from the group N, O, S.

Apart from phenyl and 1-naphthyl and 2-naphthyl, preferred aryls are:

The term “heteroaryl” by itself or as part of another substituent includes aromatic ring systems with up to 3 rings and with up to 3 identical or different heteroatoms N, S, O, in which at least 1 ring system is aromatic, and those with up to 3 substituents, preferably up to 1 substituent, wherein the substituents independently can have the meaning C₁-C₆ alkyl, OH, NO₂, CN, CF₃, OR11, SH, SR11, C₁-C₆ alkylhydroxy, C₁-C₆ alkyl-OR11, COOH, COOR11, NH₂, NHCOR11, NHR11, NR11R12, halogen, or phenyl, wherein the residues R11 und R12 independently can have the above indicated meanings.

Preferred heteroaryls are:

The term “ring system” generally refers to rings with 3, 4, 5, 6, 7, 8, 9, or 10 members. Preferred are rings with 5 and 6 members. Furthermore, ring systems with one or 2 annealed rings are preferred.

The compounds of Formula I may be present as such, or, if they contain acidic or basic groups, in the form of their salts with physiologically tolerable bases or acids. Examples for such acids are: hydrochloric acid, citric acid, trifluoracetic acid, tartaric acid, lactic acid, phosphoric acid, methane sulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, succinic acid, hydroxysuccinic acid, sulfuric acid, glutaric acid, aspartic acid, pyruvic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid, and acetylglycine. Examples for bases are alkali ions, preferably Na, K, particularly preferred the tri-potassium and tri-sodium salts, alkaline earth ions, preferably C, Mg, ammonium ions.

The compounds according to the invention may be administered orally in the usual way. The application may also be i.v., i.m., with vapors, or sprays through the nasopharynx.

The dosage depends on age, condition and weight of the patient as well as on the type of application. Usually, the daily dose of the active ingredient per person is between 0.1 μg/kg and 1 g/kg orally. This dosage may be given as 2 to 4 split dosages, or once per day as a slow release form.

The novel compounds may be used in the usual solid or liquid pharmaceutical application forms, e.g. as tablets, film tablets, capsules, powder, granules, coated tablets, solutions, or sprays. These are produced in the usual way. The agents can be processed with the usual pharmaceutical adjuvants such as tablet binders, fillers, preservatives, disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardation agents, antioxidants, and/or propellants (see H. Sucker et al.: Pharmazeutische Technologie, Thieme- Verlag, Stuttgart, 1978). Usually, the so obtained application forms contain the active ingredient in amounts of 0.1 to 99 percent per weight.

Experimental Part

Fredericamycin A can be prepared by fermentation or fully synthetically according to the known methods. The reduced forms of the Formulas Ib and IIb can be obtained from the appropriate compounds of Formulas Ia and Ia using mild reducing agents.

Preparation of the Substances

For synthesis of water soluble fredericamycin derivatives, fredericamycin (1) was first hydroxylized with osmium(IV)oxide at the diene side chain. The resulting compound (2) shows significantly higher water solubility compared to the original compound fredericamycin (1). In order to further increase the water solubility, (2) was transformed into the tri-potassium salt (3) (see diagram 1).

The fredericamycin tetrol (2) serves, among others, as an important intermediate for the synthesis of other fredericamycin derivatives with increased solubility and/or better action profile. By iodate cleavage with sodium periodate or carrier-bound periodate, the tetrol side chain may be degraded with very high yields to fredericamycin aldehyde (4) (see diagram 2).

The fredericamycin aldehyde (4) can be reacted with acylhydrazones, hydroxylamine, and O-alkylhydroxylamine to the appropriate hydrazone (see diagram 3), or oxime and oximether (see diagram 4). The reaction can be performed at room temperature in solvents such as DMF or pyridine, and is finished after a few minutes to hours.

Synthesis of Hydrazones

TABLE 1 Example/ compound R m/e λ_(max)(nm) 5/118

601.3 504.0 6/119

635.2 486.0

R Compound Example

111 18

105 19

113 20

Synthesis of Oximether

TABLE 2 Example/ compound R m/e λ_(max)(nm) 7/122 —H 516.1 500.0 8/120 —CH₃ 531.2 500.0 9/121

607.2 504.0 10/123

678.1 504.0 21/116

630.1 504.0

Analogously, the compounds 100-242 can be generated according to the instructions below (table 3). The hereby used hydrazines, hydrazones and hydroxylamines are available commercially, or have been produced according to instructions known from the literature.

TABLE 3 Formula for table 3:

Calculated Actual Example/Compound R1 R2 mass mass UV_(max) Yield 100

592.1230 593.10 500 95 C₅H₅N₂ H 101

661,1056 662,11 500 95 C₅H₃F₃N₃ H 102

620,1179 621,11 492 95 C₆H₅N₂O H 103

620,1179 621,11 500 95 C₆H₅N₂O H 104

567,1026 568,11 500 80 C₂H₂N₃ H 105 (19)

583,1339 584,10 492 95 C₃H₆N₃ H 106

609,1019 610,09 492 95 C₅H₄NO₂ H 107

634,1335 635,13 492 95 C₇H₇N₂O H 108

574,0794 558,05 492 95 NHCSNH₂ H 109

625,0791 626,08 492 95 C₅H₄NOS H 110

672,1492 673,15 492 95 C₁₀H₉N₂O H 111

598,1699 599,14 492 95 C₅H₁₁N₂ H 112

586,0971 587,10 492 95 C₂H₃N₂O₂ H 113 (20)

631,0,55 632,05 500 95 C₃H₂NOS₂ H 114

582,1022 583,13 492 95 C₃H₃N₂O H 115

634,1335 635,16 492 70 C₇H₇N₂O H 116

629,1645 630,14 492 85 C₆H₁₂NO₂ H 117

557,1182 558,11 500 95 CH₄N₃ H 118

600,1492 601,16 492 85 C₄H₉N₂O H 119

635,1414 635,13 495 85 C₇H₈N₂O H 120 (8)

530,0961 531,12 492 90 OMe H 121 (9)

606,1274 607,16 492 95 OCH₂Ph H 122

516,0804 517,11 482 95 OH H 123 (10)

678,1332 679,14 500 95 C₆H₁₁O₆ H 124

634,1335 635,15 492 95 C₇H₇N₂O 125

558,1022 559,12 492 95 NHCONH₂ H 126

640,1805 614,13 492 95 C₇H₁₃N₂O H 127

640,0884 641,10 492 95 C₇H₆ClO H 128

640,0900 641,10 492 95 C₅H₅N₂OS H 129

623,1288 624,13 500 90 C₅H₆N₃O H 130

614,1284 615,13 492 95 C₄H₇N₂O₂ H 131

655,1914 656,19 492 50 C₇H₁₄N₃O H 132

642,1597 643,17 492 60 C₆H₁₁N₂O₂ H 133

586,1335 587,15 492 70 C₃H₇N₂O H 134

628,1805 629,17 492 70 C₆H₁₃N₂O H 135

587,1539 588,14 492 90 C₄H₁₀NO H 136

752,1885 753,19 492 85 C₁₃H₁₈ClN₂O H 137

601,1696 602,19 492 70 C₅H₁₂NO H 138

626,0840 627,07 500 95 C₅H₅N₂ Cl 139

695,0666 696,06 500 95 C₅H₃F₃N₃ Cl 140

654,0789 655,07 500 95 C₆H₅N₂O Cl 141

654,0789 655,07 500 95 C₆H₅N₂O Cl 142

601,0636 602,06 500 90 C₂H₂N₃ Cl 143

617,0949 618,08 500 95 C₃H₆N₃ Cl 144

643,0629 644,05 500 95 C₅H₄NO₂ Cl 145

668,0946 669,07 500 95 C₇H₇N₂O Cl 146

608,0404 609,07 500 95 NHCSNH₂ Cl 147

659,0401 660,07 500 95 C₅H₄NOS Cl 148

706,1102 707,16 500 95 C₁₀H₉N₂O Cl 149

632,1309 633,16 500 95 C₅H₁₁N₂ Cl 150

620,0582 621,09 500 95 C₂H₃N₂O₂ Cl 151

664,9965 645,31 500 95 C₃H₂NOS₂ Cl 152

616,0633 617,10 500 95 C₃H₃N₂O Cl 153

668,0946 669,13 500 95 C₇H₇N₂O Cl 154

663,1255 664,16 500 95 C₆H₁₂NO₂ Cl 155

591,0792 592,11 500 95 156

634,1102 635,14 500 95 C₄H₉N₂O Cl 157

669,1024 669,12 500 95 C₇H₈N₂O Cl 158

564,0571 565,09 500 95 OMe Cl 159

640,0884 641,12 500 95 OCH₂Ph Cl 160

550,0415 551,06 500 95 OH Cl 161

712,0943 713,10 500 95 C₆H₁₁O₆ Cl 162

668,0946 669,09 500 95 C₇H₇N₂O Cl 163

592,0633 593,07 500 90 NHCONH₂ Cl 164

674,1415 675,11 500 95 C₇H₁₃N₂O Cl 165

674,0494 675,03 500 90 C₇H₆ClO Cl 166

674,0510 675,02 500 95 C₅H₅N₂OS Cl 167

657,0898 658,06 500 95 C₅H₆N₃O Cl 168

648,0895 649,07 500 95 C₄H₇N₂O₂ Cl 169

689,1524 690,15 500 60 C₇H₁₄N₃O Cl 170

676,1208 677,13 500 60 C₆H₁₁N₂O₂ Cl 171

620,0946 621,11 500 70 C₃H₇N₂O Cl 172

662,1415 663,12 500 70 C₆H₁₃N₂O Cl 173

621,1150 622,10 500 60 C₄H₁₀NO Cl 174

786,1495 787,16 500 90 C₁₃H₁₈ClN₂O Cl 175

635,1306 636,10 500 75 C₅H₁₂NO Cl 176

670,0334 670,99 500 95 C₅H₅N₂ Br 177

739,0161 739,99 500 95 178

698,0284 699,00 500 90 C₆H₅N₂O Br 179

698,0284 699,00 500 90 C₆H₅N₂O Br 180

645,0130 645,99 492 70 C₂H₂N₃ Br 181

661,0443 662,01 492 95 C₃H₆N₃ Br 182

687,0124 688,99 492 95 C₅H₄NO₂ Br 183

712,0440 713,03 500 95 C₇H₇N₂O Br 184

651,9899 653,04 500 95 NHCSNH₂ Br 185

702,9895 704,02 492 95 C₅H₄NOS Br 186

750,0597 751,10 500 95 C₁₀H₉N₂O Br 187

676,0804 677,10 492 95 C₅H₁₁N₂ Br 188

664,0076 665,05 500 95 C₂H₃N₂O₂ Br 189

708,9460 709,99 492 95 C₃H₂NOS₂ Br 190

660,0127 661,05 492 95 C₃H₃N₂O Br 191

712,0440 713,08 492 70 C₇H₇N₂O Br 192

707,0750 708,06 500 95 C₆H₁₂NO₂ Br 193

635,0287 636,02 500 95 CH₄N₃ Br 194

678,0597 679,06 500 95 C₄H₉N₂O Br 195

713,0518 713,03 500 95 C₇H₈N₂O Br 196

608,0066 609,03 492 95 OMe Br 197

684,0379 685,05 492 95 OCH₂Ph Br 198

593,9909 595,01 492 95 OH Br 199

756,0437 757,00 500 90 C₆H₁₁O₆ Br 200

712,0440 713,00 500 90 C₇H₇N₂O Br 201

636,0127 637,00 492 90 NHCONH₂ Br 202

718,0910 719,00 500 90 C₇H₁₃N₂O Br 203

717,9989 718,00 492 95 C₇H₆ClO Br 204

718,0004 718,97 492 95 C₅H₅N₂OS Br 205

701,0392 702,01 500 95 C₅H₆N₃O Br 206

692,0389 693,03 492 95 C₄H₇N₂O₂ Br 207

733,1018 734,10 500 90 C₇H₁₄N₃O Br 208

720,0702 721,10 500 95 C₆H₁₁N₂O₂ Br 209

664,0440 665,08 500 95 C₃H₇N₂O Br 210

706,0910 707,09 500 90 C₆H₁₃N₂O Br 211

665,0644 666,08 500 95 C₄H₁₀NO Br 212

830,0989 831,11 500 95 C₁₃H₁₈ClN₂O Br 213

679,0801 680,09 492 95 C₅H₁₂NO Br 214

558,1274 559,21 500 99 Oi—Pr H 215

600,1743 601,30 500 99 O-n-hex H 216

624,1180 625,28 500 99 C₇H₆FO H 217

640,0884 641,27 500 99 C₇H₆ClO H 218

624,1180 625,31 500 99 C₇H₆FO H 219

592,0884 593,28 500 80 Oi—Pr Cl 220

634,1354 635,36 500 90 O-n-hex Cl 221

658,0790 659,32 500 85 C₇H₆FO Cl 222

674,0494 675,31 500 80 C₇H₆ClO Cl 223

658,0790 659,34 500 80 C₇H₆FO Cl 224

636,0379 639,30 492 90 Oi—Pr Br 225

678,0848 679,37 492 95 O-n-hex Br 226

702,0284 703,34 492 95 C₇H₆FO Br 227

717,9989 719,34 492 95 C₇H₆ClO Br 228

702,0284 705,35 492 95 C₇H₆FO Br 229

684,0200 685,30 500 99 Oi—Pr I 230

726,0669 727,41 500 99 O-n-hex I 231

750,0105 751,38 500 99 C₇H₆FO I 232

765,9810 767,36 500 99 C₇H₆ClO I 233

750,0105 751,38 500 99 C₇H₆FO I 234

732,0200 733,38 500 99 OCH₂Ph I 235

755,0571 756,33 500 99 C₆H₁₂NO₂ I 236

655,9887 657,32 492 95 OMe I 237

765,9810 767,38 492 99 C₇H₆ClO I 238

878,0810 879,45 500 99 C₁₃H₁₈ClN₂O I 239

641,9730 643,31 492 99 OH I 240

781,0840 782,39 500 99 C₇H₁₄N₃O I 241

768,0523 769,38 500 99 C₆H₁₁N₂O₂ I 242

711.9897 713.37 500 99 C₂H₃N₂O₂ I Reduction and Oxidation of Fredericamycin Aldehyde (4)

Fredericamycin aldehyde (4) can be reacted with a common reducing agent such as sodium borohydrid in a solvent such as DMF or pyridine to hydroxymethyl fredericamycin (11). The reaction can be summarized as a single pot reaction (iodate cleavage of fredericamycin tetrol (2) to fredericamycin aldehyde (4) (see diagram 2) and reduction without isolation of the intermediates to fredericamycin alcohol (11)).

Fredericamycin aldehyde (4) can be oxidized with the oxidizing agent sodium chlorite (NaClO₂), a buffer such as sodium dihydrogenphosphate in presence of an alkene such as 2,3-dimethylbutene with very good yields to fredericamycin carboxylic acid (12). The usually employed oxidation methods such as those being used in preparative chemistry for the oxidation of aldehydes to carboxylic acids (oxidation with chromium(VI) compounds, manganese(VII) compounds as well as peroxo acid) did not lead to success. Only the use of the above described oxidation method provided the desired product. The literature describes oxidations of 2-pyridone-6-aldehydes with silver ions and potassium permanganate in an alkaline medium. This method, however, is not suited for fredericamycin and its derivatives since fredericamycin (1) contains base-labile (-reactive) groups (OH groups) causing undesired side reactions.

The potassium salt of the fredericamycin acid (13) was obtained according to a common method by stoichiometric neutralization.

Substitution in the B Ring

Fredericamycin (1) can be reacted with halogenation agents such as N-bromosuccinimide (NBS) and N-iodosuccinimide (NIS) with good yields to the substituted 5-bromo or 5-iodo fredericamycin derivatives (14) and (15) (diagram 6). The fredericamycin aldehyde (4) and (36) can be transformed with elemental bromine, NBS, BrI, NIS, and NCS to the appropriate halogen-substituted fredericamycin aldehyde (37), (38) and (39).

The appropriate fluorine compound is accessible, too.

Both of the two following fredericamycin compounds (23) and (24) are also precursors. (23) is the precursor for an amino acid-linked fredericamycin derivative.

The preparation of (23) may be recognized as proof that the aldehyde (4) may be reacted with phosphorylides according to Wittig or Wittig-Horner (see diagram 7).

The compound (24) is the precursor of an N-methylated fredericamycin derivative (diagram 8).

Fredericamycin may be transformed by palladium/hydrogen almost quantatively to tetrahydro fredericamycin (25), and may be halogenated in the nucleus according to the above described methods, e.g. to the bromine compound (26) (diagram 9):

Surprisingly it has also been found that the methoxy groups in fredericamycin and the derivatives according to the invention can be exchanged under alkali or earth alkali acetate catalysis by oxygen nucleophiles such as alcohols or polyols. Thereby, the alcohols can carry a multitude of different substituents (table 4).

TABLE 4 UV_(max) Yield Example R1 R2 R3 (nm) m/e (%) 243

H

504 (M + H) 554 97 244

H

500 (M+) 582 96 245

H

500 (M + H) 568 70 246

H

504 (M + H) 597 36 247

Br

504 (M+) 632/634 71 248

H

500 (M + H) 566 91 249

H

499 (M+) 569 52 250

H

504 (M + H) 616 99 251

H

500 (M+) 580 99 252

H

499 (M + H) 622 20 253

H

500 (M + H) 669 99 254

H

504 (M + H) 653 48 255

H

504 (M + H) 594 50 256

H

499 (M + H) 632/634 99 Exchange of the Methoxy Group at the F Ring

The exchange of the methoxy groups at the F ring of the fredericamycin and at the derivatives is possible by primary, secondary or aromatic amines. Thereby, the components are stirred with the appropriate primary or secondary amines at room temperature in DMF or in another inert solvent. With aromatic amines, a catalysis with Lewis acids such as stannous(IV)chloride, etc. is required.

TABLE 5 R1

Example I

257 I

258 Br

259 H

260 H

261 H

262 H

263 H

264 H

265 I

266 H

267 H

268 H

269 Br

270 Preparation of Heterocyclic Fredericamycin Derivatives

The fredericamycin aldehyde (4) can be reacted to pyridal acetone (271) according to Wittig or Wittig-Horner. Bromation with bromine in DMF yields the dibromo-derivative (272) substituted in the side chain and at the B ring. With the appropriately substituted thioamides or thioureas, the respective thiazole derivatives (273-276) are accessible.

TABLE 6 R Example NH₂ 273 Ph 274 CH₃CONH 275 CH₃ 276 Preparation of Thioanalogoues of Fredericamycin Derivatives

By sulfurization of fredericamycin or its derivatives with Lawesson reagent or P₄S₁₀ in pyridine, the derivatives analogous to thiopyridone are accessible (see diagram 13).

Fredericamycin (1) forms inclusion compounds such as (25) with polysugars such as α-cyclodextrin, that have good water solubility compared to the original substance.

The dextrin inclusion compounds form easily if the components are mixed in the appropriate stoichiometric ratio in a suitable solvent such as DMSO (see diagram 11).

Biological Activity Against 12 Cancer Cell Lines:

LCL (H460, lung), MACL (MCF7, breast), LXFL (52L, lung), LXFA (629L, lung), MEXF (462NL, melanoma), MEXF (514L, melanoma), MAXF (401NL, breast), RXF (944L, renal), RXF (486L, renal), UXF (1138L, uterus), PRXF (PC3M, prostate), PRXF (22RV1).

Efficacy (IC70) Averaged Over all Cell Lines in μg/mL at 5 Test Concentrations TABLE 7 Example/reference IC70 μg/mL adriamycin 0.0210 cisplatin 37.1020 fredericamycin 0.2790 1 0.1130 13 0.0050 14 0.0070 22 0.0080 23 0.0110 121 0.2020 127 0.1550 192 0.0750 196 0.0950 197 0.0340 198 0.2560 203 0.1590 212 0.2100 214 0.0220 215 0.0720 217 0.1290 218 0.0760 224 0.0470 225 0.1110 230 0.0910 232 0.3170 233 0.1000 234 0.0520 235 0.0810 236 0.1210 265 0.1330 275 0.3680 276 0.0840

EXAMPLES Example 1 1-Desoxy-5-C-[(8R)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphalene]-3-yl]pentitol (2)

Two hundred (200) mg (0.38 mmol) fredericamycin A (1) are dissolved in 30 mL dichloromethane. After addition of 20 mL methanol and 4.4 ml water, 350 mg (2.6 mmol) N-methylmorpholine-N-oxide are added. Under vigorous stirring, 0.2 ml of a 2.5% osmium(IV)oxide solution in t-butanol is added dropwise. The reaction mixture is acidified with 2-3 drops of trifluoracetic acid. After stirring for 48 hours, the reaction is complete according to HPLC control (RP18, acetonitrile water (0.2% acetic acid)). The reaction mixture is added to 400 ml water under vigorous stirring, and the dark red crystalline solid is sucked off through a filter. Drying in HV. Yield: 195 mg (87% of the theoretical value) dark red powder. ES⁻: M/e=606.2 (M+−H), λ_(max): 504.0.

Example 2 Tri-potassium-1-desoxy-5-C-[(8R)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]pentitol (3)

Twelve (12.0) mg (19.8 μmol) fredericamycin tetrol (2) are dissolved in 1.5 mL absolute pyridine under nitrogen atmosphere. The solution is gassed for 30 min with argon at 0° C. Under the argon atmosphere, 5.94 mL of a 0.01 N KOH solution are added at once at 0° C. The reaction solution immediately turns turquoise. The reaction mixture is stirred for another 1 hour, and subsequently is frozen and lyophilized. Yield: 13.2 mg (100% of the theoretical value); deep blue crystal mass.

Example 3 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde (4)

1.) Fifty (50) mg (82.3 μmol) tetrahydroxy fredericamycin (tetrol (2)) are dissolved in 4 mL DMF. Under vigorous stirring, an aqueous sodium iodate solution (300 mg NaIO₄ in 1 mL water) is added dropwise within one hour. After 1 h stirring at room temperature, 2 drops of trifluoracetic acid are added. After stirring for another 30 min, the reaction solution is diluted with 3 ml DMF, and 150 mg NaIO₄ dissolved in 0.5 ml water are added.

After another hour, 100 mL water are added. The supernatant over the precipitate is sucked off, and dryed in HV. Dark red crystal powder. Yield: 41 mg (100% of the theoretical value). M/e=501.3, UV_(max): 504.0 nm.

2.) One hundred and nine (109) mg (179 μmol) fredericamycin tetrol (2) are dissolved in 8 mL pyridine. 180 μL water are added. To the reaction mixture, 450 mg (1.08 mmol, 6 eq.) (polystryrylmethyl)trimethylammonium periodate resin are added. Then the mixture is stirred for 12 h at RT. The resin is filtered off; washing and concentrating until dry. Dark red residue.

Yield: 89.9 mg (100% of the theoretical value). M/e=501.3, UV_(max): 504.0 nm.

Example 4 1-[2-Oxo-2-((2E)-2-{[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]methylene)ethyl]-dimethylamino trifluoroacetate (118)

Twenty (20) mg (39.9 μmol) fredericamycin aldehyde (4) are dissolved under argon in 1.5 mL absolute DMF. Addition of 9.1 mg (47.9 μmol, 1.2 eq.) acetylhydrazide dimethylammoniumchloride (Girard reagent D) and 20 mg polyvinylpyridine (2% DVB). The mixture is stirred for 2.5 h. Then, 27 mg (80 μmol, 2.0 eq.) aldehyde Wang resin (coating: 3.0 mmol/g) are added and stirred for another 1 h. Then, the resin is filtered, and washed 3× with DMF. Concentration in high vacuum. The residue is dissolved in 1 ml trifluoracetic acid, and concentrated after 10 min until dry.

Red solid; Yield: 28.5 mg (100%); ES⁺: M/e=601.3, UV_(max): 504.0 nm.

Example 5 1-[2-Oxo-2-((2E)-2-{[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]methylene}hydrazino)-ethyl]pyridinium chloride (119)

Fifteen (15) mg (29.9 μmol) fredericamycin aldehyde (4) are dissolved in 3 mL DMF. At room temperature 7.5 mg (40.0 μmol) acethydrazinopyridinium chloride (Girard reagent P) dissolved in 75 μL water are added. The reaction mixture is stirred for 1.5 h at room temperature, and the course of the reaction is monitored by HPLC. When finished, acetic acid ethyl ester is added to the reaction mixture, until a precipitation occurs. After the crystallization is finished, the red solid is sucked off.

Yield: 9.1 mg (44% of the theoretical value). M/e=635.2; λ_(max): 486.0.

Example 6 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde oxime (122)

Ten (10) mg (19.4 μmol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 3.1 mg (44.6 μmol) hydroxylammonium chloride, 3.2 μl pyridine are added. Stirring for 2 h at room temperature. The reaction mixture is added to 50 ml water and extracted 3 times with ethyl acetate. After drying and concentration, a deep red amorphous crystal powder was left (HPLC clean).

Yield: 7.4 mg (72% of the theoretical value). ES⁻: M/e=516.1; λ_(max): 500.0 nm.

Example 7 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-methyloxime (8)

Ten (10) mg (19.4 μmol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 3.4 mg (40.7 μmol) O-methylhydroxylammonium chloride and 3.2 μl pyridine, the reaction mixture is stirred for 2 h at room temperature. Then, it is added to 100 ml water, and the supernatant is sucked off from the red precipitate (HPLC clean).

Yield: 7.6 mg (71% of the theoretical value). ES⁺: M/e=531.2; λ_(max): 500.0.

Example 8 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-benzyloxime (9)

Ten (10) mg (19.4 μmol) fredericamycin aldehyde (4) are dissolved in 2 mL DMF. After addition of 6.4 mg (43.2 μmol) O-benzylhydroxylammonium chloride and 3.2 μl pyridine, the reaction mixture is stirred for 2 h at room temperature. Then, it is added to 50 ml water, and the supernatant is sucked off from the red precipitate (HPLC clean).

Yield: 6.8 mg (57% of the theoretical value). ES⁺: M/e=607.2; λ_(max): 504.0 nm.

Example 9 1-O-({(1E)-[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]methylene}amino)-β-D-glucopyranose (10)

Two (2.0) mg (4.0 μmol) fredericamycin aldehyde (4) are dissolved in 150 μL DMF, and 0.86 mg (4.4 μmol) β-aminoxy-D-glucopyranose is added. The mixture is stirred for 24 h at room temperature, and 5 mg (15.0 μmol) aldehyde Wang resin (coating: 3.0 mmol/g) is added. After stirring for another 3 h, the resin is filtered off, washed with DMF, and the filtrate is concentrated in high vacuum until dry.

Yield: 2.7 mg (99% of the theoretical value), red powder; ES⁻: M/e=678.1; λ_(max): 504.0 nm.

Example 10 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (11)

Thirty (30) mg (49.4 μmol) tetrahydroxy fredericamycin (2) were dissolved in 2 mL pyridine. Twenty (20) mg (93.0 μmol) sodium metaperiodate dissolved in 0.3 ml water are added. After stirring for 4 h, 10 mg (260 μmol) sodium borohydride are added. After 12 h, concentration until dry, and the residue is separated by preparative HPLC.

Yield: 2.6 mg (13% of the theoretical value) red powder. ES⁻: M/e=503.2; λ_(max): 504.0 nm.

Example 11 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carboxylic acid (12)

Fifteen (15) mg (29.9 μmol) fredericamycin aldehyde (4) are dissolved in 1 mL dichloromethane and 0.5 ml t-butanol. Addition of 250 μl 2,4-dimethylbutene. Under stirring at room temperature, a solution of 6.0 mg (53.1 μmol) sodium chlorite (80%) and 5.1 mg sodium hydrogenphosphate in 250 μl water are added dropwise.

After 2.5 h, again a solution of 10.0 mg (88.5 μmol) sodium chlorite and 5 mg sodium dihydrogenphosphate in 200 μl water are added. After altogether 4 h, it is put on water, and extracted with ethyl acetate.

The raw mixture was purified by preparative HPLC (RP18, acetonitrile-water-acetic acid). Red amorphous powder.

Yield: 68.3 mg (53.5% of the theoretical value). E⁻: M/e=516.1; λ_(max): 504.0 nm.

Example 12 Potassium(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carboxylate (13)

6.9 mg (13.3 μmol) Fredericamycin carboxylic acid (12) are dissolved in 5 mL DMF under nitrogen. At room temperature and under oxygen exclusion and vigorous stirring, 1.27 mL (12.7 μmol) of an aqueous 0.01 N KOH solution is added dropwise. It is stirred for 15 minutes at room temperature, and concentrated in high vacuum until dry.

Yield: 7.40 mg (100% of the theoretical value). E⁻: M/e=516.1; λ_(max): 504.0 nm.

Example 13 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (14)

Twenty (20) mg (37.1 μmol) fredericamycin (1) were dissolved in 250 μl DMF, and then 6. 3 mg (35.3 μmol) N-bromosuccinimide in 250 μl DMF were added within one hour at 0° C. The reaction was stirred in a slowly thawing ice bath over night. Then, the DMF is removed in high vacuum, and the residue is purified by preparative HPLC.

Yield: 7 mg (32% of the theoretical value) red crystal mass. M/e=616.1/618.1; λ_(max): 486.0 nm.

Example 14 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,31,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (15)

Eighty four (84) mg (158 μmol) fredericamycin (1) were dissolved in 1.0 μl DMF, and then 33.0 mg (150.0 μmol) N-iodosuccinimide in 500 μl DMF were added within one hour at 0° C. The reaction was stirred in a slowly thawing ice bath over night. Then, the DMF is removed in high vacuum, and the residue (120 mg (14) with a content of 80%) is purified by preparative HPLC (gradient CH₃CN 50-90% over 16 min.)

Yield: 18 mg (17% of the theoretical value) red crystal mass. M/e=665.0; λ_(max): 484.0 nm.

Example 15 Methyl-2-{[(benzyloxy)carbonyl]amino}-3-[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]acrylate (23)

Sixty six (66) mg (200 μmol) Z-α-phosphonoglycine trimethylester are dissolved under argon in 1 mL absolute pyridine, and 25 pL 1,1,3,3-tetramethylguanidine are added at 0° C. After 40 min. 20 mg (40 μmol) fredericamycin aldehyde (4) is added at 0° C. After 15 min. 20 ml 1 M acetic acid is added, and the mixture is extracted 3× with acetic acid. The raw product is purified by preparative HPLC (RP18, acetonitrile-water).

Yield: 10.0 mg (36% of the theoretical value). M/e=706.4; λ_(max): 492.0 nm.

Example 16 (8S)-9-hydroxy-4′,6′,9′-trimethoxy-2-methyl-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (24)

Ten (10) mg (15 μmol) fredericamycin (1) were dissolved under protective gas in 4 ml absolute DMF. At RT, 400 μl (4311 μmol) methyliodide and 81 mg powdered potassium carbonate are added. The reactions mixture is then stirred at RT for 20 h, and is then transferred onto water. Extraction with ethyl acetate, and purification of the residue by separating chromatography on chloroform/methanol 30/1.

Yield: 4 mg (37% of the theoretical value). Yellow residue. M/e=582.3; λ_(max): 368.0 nm.

Example 17 Fredericamycin A 1:2 complex with α-cyclodextrin (22)

Ten (10) mg fredericamycin (0.025 mMol) are added to a solution of 50 mg α-cyclodextrin (0.050 mMol) in 500 μl dimethylsulfoxide. The solution is then diluted with 5 ml water. A stock solution prepared in such way can be diluted as desired with water.

λ_(max)=504.0 nm.

Example 18 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde(4-methylpiperazine-1-yl)hydrazone (111)

Five (5) mg (9.42 μmol) fredericamycin aldehyde (4) are dissolved in 500 μl DMF and 25 μl trifluoracetic acid. At room temperature, 1.30 mg (11.3 μmol) 1-amino-4-methyl-piperazine is added. After stirring for 4.5 h at room temperature, 1 equivalent each of Wang aldehyde resin and sulfonohydrazide resin is added and stirred for 2 h.

Filtration and concentration of the reaction solution at high vacuum.

Red powder. Yield: 5.4 mg (91% of the theoretical value). M/e=599 (M+H)+; λ_(max): 504.0 nm.

Example 19 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-4,5-dihydro-1H-imidazole-2-yl-hydrazone (123)

Five (5.00) mg (9.42 μmol) fredericamycin aldehyde (4) are dissolved in 500 μl DMF and 25 μl trifluoracetic acid. At room temperature, 2.05 mg (11.3 μmol) 2-hydrazino-2-imidazolin hydrobromide is added. After stirring for 4.5 h at room temperature, 1 equivalent each of Wang aldehyde resin and sulfonohydrazide resin are added and stirred for 2 h. Separation of the resin by filtration and concentration of the reaction solution at high vacuum.

Red powder. Yield: 3.9 mg (67% of the theoretical value). M/e=584 (M+H)+; λ_(max): 504.0 nm.

Example 20 4′,9,9′-Trihydroxy-6′-methoxy-3-{(E)-[(4-oxo-2-thioxo-1,3-thiazolidin-3-yl)imino]methyl)-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (123)

Five (5.00) mg (9.42 μmol) fredericamycin aldehyde (4) are dissolved in 500 μl DMF and 25 μl trifluoracetic acid. At room temperature, 1.67 mg (11.3 μmol) 2N-aminorhodanide are added. After stirring for 4.5 h at room temperature, 1 equivalent each of Wang aldehyde resin and sulfonohydrazide resin are added and stirred for 2 h.

Filtration and concentration of the reaction solution.

Red powder. Yield: 4.1 mg (65% of the theoretical value). M/e=599 (M+H)+; λ_(max): 504.0 nm.

Example 21 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-(2-morpholine-4-ylethyl)oxime (27)

Five (5.00) mg (9.42 μmol) fredericamycin aldehyde (4) are dissolved in 500 μl DMF and 25 μl trifluoracetic acid. At room temperature, 2.47 mg (11.3 μmol) N-(aminoxyethyl)morpholine dihydrochloride is added. After stirring for 4.5 h at room temperature, 1 equivalent of Wang aldehyde resin (3.1 mg, 9.4 μmol, coating: 3.0 mmol/g) as well as 1 equivalent sulfonohydrazide resin (6.1 mg, 9.4 mmol, 1.5 mmol) are added and stirred for 2 h.

Filtration and concentration of the reaction solution.

Red powder. Yield: 6.1 mg (98% of the theoretical value). M/e=630 (M+H)+; λ_(max): 504.0 nm.

Example 22 (8S)-5-chloro-4′,6′,9′-trimethoxy-2-methoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (34)

Three hundred (300) mg (556.6 μmol) fredericamycin (1) are dissolved under argon in 10 μl DMF, and then 75.0 mg (556.6 μmol) N-chlorosuccinimide are added. The reaction is stirred for 5 h at 40° C. The reaction mixture is then added to 400 ml methanol/water 1:1, and the red precipitate is sucked off and dried at high vacuum.

Yield: 305 mg (96% of the theoretical value) red crystal mass. M/e=573/575; λ_(max): 504.0 nm.

Example 23 (8S)-5-fluoro-4′,9,9′-trihydroxy-6′-methoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (35)

Fifty (50) mg (92.8 μmol) fredericamycin (1) are dissolved in 5 ml DMF under argon, and then 33.0 mg (93.5 μmol) 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) Selectfluor (is added. The reaction is stirred for 24 h at room temperature. The reaction mixture is then added to 200 ml water, and is extracted with ethyl acetate. The concentrated raw product is purified by preparative HPLC (RP18, acetonitrile- water-acetic acid).

Yield: 7.1 mg (14% of the theoretical value) red crystal mass. M/e=557; λ_(max): 504.0 nm.

Example 24 1-Desoxy-5-C-[(8R)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]-pentitol (36)

Hundred twenty (120) mg (209 mmol) chlorofredericamycin (34) are dissolved in 25.0 ml dichloromethane. After addition of 3.6 ml methanol and 0.8 ml water, 197 mg (1.46 mmol) N-methylmorpholine-N-oxide is added. Under vigorous stirring, 0.12 ml of a 2.5% solution of osmium(IV)oxide in t-butanol is added dropwise. After stirring for 27 hours, the reaction is complete, according to HPLC monitoring (RP18, acetonitrile-water (0.2% acetic acid)). The reaction mixture is added to 200 ml water under vigorous stirring, and the dark red solid is sucked off. Drying in HV.

Yield: 101 mg (75% of the theoretical value) dark red powder. M/e=641/643; λ_(max): 504.0.

Example 25 (8S)-4′,9,9′-trihydroxy-5-bromo-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde (37)

Hundred (100) mg (200 μmol) fredericamycin aldehyde (4) are dissolved under argon in 5 ml DMF. Then, 200 μl of a 1M bromine solution in DMF is added. After stirring for 1.5 h at RT, another 20 μl bromine solution are added. According to HPLC monitoring, the reaction mixture is complete after 3.5 h.

Add to 150 ml water, and shake out with dichloromethane.

Yield: 96 mg (83% of the theoretical value) dark red powder. M/e=579/581; λ_(max): 504.0.

Example 26 1,2,3,4-Tetrahydro-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (26)

Eight (8.0) mg (0.0128 mmol) 1,2,3,4-tetrahydrofredericamycin (25) are dissolved in 1 ml absolute DMF under nitrogen. Then a solution of 2.3 mg (0.0128 mmol) bromine in 0.25 ml DMF is added dropwise to the solution. Stirring at room temperature over 24 h. The reaction mixture is concentrated to half volume in high vacuum, and is then transferred onto 100 ml water. The supernatant is sucked off from the precipitate and dried in a vacuum.

Red crystal powder 8.1 mg (88% of the theoretical value) m/e=621/623; λ_(max): 499 nm.

Example 27 (8S)-4′,9,9′-trihydroxy-6′-benzylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone

Twenty (20) mg (37.1 μmol) fredericamycin are dissolved in 1 ml DMF under argon, then 4.76 mg (44.50 μmol) benzylamine are added at room temperature. According to HPLC (RP18, acetonitrile/water), a homogenous new product has formed after 3 h. The reaction mixture is concentrated at high vacuum until dry.

Red crystal mass; Yield: 23 mg (100% of the theoretical value) M/e=615.3 (M+H); λ_(max): 492 nm.

Example 28 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-benzylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone

Five (5.0) mg (8.71 μmol) 5-chlorofredericamycin are dissolved in 1 ml DMF under argon, then 1.12 mg (10.45 μmol) benzylamine are added at room temperature. After 29 h, the reaction mixture is concentrated at high vacuum until dry.

Red crystal mass; Yield: 5 mg (89% of the theoretical value) M/e=649.1 (M+H); λ_(max): 492 nm.

Example 28 Translator: 28a (8S)-4′,9,9′-trihydroxy-6′-ethanolamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone

Ten (10) mg (18.6 μmol) fredericamycin are dissolved in 1 ml DMF under argon, then 1.36 mg (22.3 μmol) ethanolamine are added at room temperature. According to HPLC (RP18, acetonitrile/water), a homogenous new product has formed after 3 h. The reaction mixture is concentrated at high vacuum until dry.

Red crystal mass; Yield: 9 mg (85% of the theoretical value) M/e=569.3 (M+H); λ_(max): 500 nm.

Example 29 (8S)-4′,9,9′-trihydroxy-6′-(4-piperidylmethylamino)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone

Ten (10) mg (18.6 μmol) fredericamycin are dissolved in 1 ml DMF under argon, then 2.7 PI (22.3 μmol) 4-aminomethylpiperidine are added at room temperature. The reaction mixture is concentrated at high vacuum until dry after 24 h.

Red crystal mass; Yield: 11 mg (99% of the theoretical value) M/e=622.3 (M+H); λ_(max): 492 nm.

Examples 100-142

The compounds 100-142 can be generated analogously to examples 7, 8, 9, 10, 18, 19 and 20:

Example 100 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydepyridine-2-yl-hydrazone (100)

Yield: (95% of the theoretical value) MS: M/e=593.1; λ_(max): 500.0 nm.

Example 101 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde [4-(trifluoromethyl)pyrimidine-2-yl]hydrazone (101)

Yield: (95% of the theoretical value) MS: M/e=562.1; λ_(max): 500.0 nm.

Example 102 N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]pyridyl-3-carbohydrazine (102)

Yield: (95% of the theoretical value) MS: M/e=621.1; λ_(max): 492.0 nm.

Example 103 N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]isonicotinohydrazine (103)

Yield: (95% of the theoretical value) MS: M/e=621.1; λ_(max): 500.0 nm.

Example 104 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-1,2,4-triazole-4-ylhydrazone (104)

Yield: (80% of the theoretical value) MS: M/e=568.1; λ_(max): 500.0 nm.

Example 105 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-4,5-dihydro-1H-imidazole-2ylhydrazone (105)

Yield: (95% of the theoretical value) MS: M/e=584.1; λ_(max): 492.0 nm.

Example 106 N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-2-furohydrazine (106)

Yield: (95% of the theoretical value) MS: M/e=610.0; λ_(max): 492.0 nm.

Example 107 4-Amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]benzohydrazine (107)

Yield: (95% of the theoretical value) MS: M/e=635.1; λ_(max): 492.0 nm.

Example 108 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydethiosemicarbazone (108)

Yield: (95% of the theoretical value) MS: M/e=558.0; λ_(max): 492.0 nm.

Example 109 N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]thiophene-2-carbohydrazine (109)

Yield: (95% of the theoretical value) MS: M/e=626.0; λ_(max): 492.0 nm.

Example 110 2-(1H-indole-3-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazine (110)

Yield: (95% of the theoretical value) MS: M/e=673.1; lλ_(max): 492.0 nm.

Example 111 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde(4-methylpiperazine-1-yl)hydrazone (111)

Yield: (95% of the theoretical value) MS: M/e=599.1; λ_(max): 492.0 nm.

Example 112 2-Oxo-2-{(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-hydrazino)acetamide (112)

Yield: (95% of the theoretical value) MS: M/e=587.1; λ_(max): 492.0 nm.

Example 113 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (113)

Yield: (95% of the theoretical value) MS: M/e=632.0; λ_(max; λ) _(max):500.0 nm.

Example 114 1(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-hydrazino}acetonitrile (114)

Yield: (95% of the theoretical value) MS: M/e=583.1; λ_(max): 492.0 nm.

Example 115 2-Amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]benzohydrazine (115)

Yield: (95% of the theoretical value) MS: M/e=635.1; λ_(max): 492.0 nm.

Example 116 4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-morpholine-4-yl-ethyl]oxime (116)

Yield: (85% of the theoretical value) MS: M/e=630.1; λ_(max): 492.0 nm.

Example 117 (2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazinecarboximidamide (117)

Yield: (95% of the theoretical value) MS: M/e=558.1; λ_(max): 500.0 nm.

Example 118 2-(Dimethylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazine (118)

Yield: (85% of the theoretical value) MS: M/e=601.1; λ_(max): 492.0 nm.

Example 119 1-[2-Oxo-2-((2E)-2-{[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene}hydrazino)ethyl]pyridinium chloride (119)

Yield: (85% of the theoretical value) MS: M/e=635.1; λ_(max): 492.0 nm.

Example 120 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-methyloxime (120)

Yield: (90% of the theoretical value) MS: M/e=531.1; λ_(max): 492.0 nm.

Example 121 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-benzyloxime (121)

Yield: (95% of the theoretical value) MS: M/e=607.1; λ_(max): 492.0 nm.

Example 122 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde oxime (122)

Yield: (95% of the theoretical value) MS: M/e=517.1; λ_(max): 482.0 nm.

Example 123 1-O-({(1E)-[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene}amino)-β-D-glucopyranose (123)

Yield: (95% of the theoretical value) MS: M/e=679.1; λ_(max): 500.0 nm.

Example 124 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-phenylsemicarbazone (124)

Yield: (95% of the theoretical value) MS: M/e=635.1; λ_(max): 492.0 nm.

Example 125 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydesemicarbazone (125)

Yield: (95% of the theoretical value) MS: M/e=559.1; λ_(max): 492.0 nm.

Example 126 2-Piperidino-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (126)

Yield: (95% of the theoretical value) MS: M/e=641.1; λ_(max): 492.0 nm.

Example 127 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-chlorobenzyl)oxime (127)

Yield: (95% of the theoretical value) MS: M/e=641.1; λ_(max): 492.0 nm.

Example 128 N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-(2-methyl-1,3-thiazole-4yl)carbohydrazide (128)

Yield: (95% of the theoretical value) MS: M/e=641.1; λ_(max): 492.0 nm.

Example 129 2-(1H-imidazole-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (129)

Yield: (90% of the theoretical value) MS: M/e=624.1; λ_(max): 500.0 nm.

Example 130 2-(Acetylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (130)

Yield: (95% of the theoretical value) MS: M/e=615.1; λ_(max): 492.0 nm.

Example 131 2-(4-Methylpiperazine-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (131)

Yield: (50% of the theoretical value) MS: M/e=656.1; λ_(max): 492.0 nm.

Example 132 2-Morpholine-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (132)

Yield: (60% of the theoretical value) MS: M/e=643.1; λ_(max): 492.0 nm.

Example 133 2-(Methylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (133)

Yield: (70% of the theoretical value) MS: M/e=587.1; λ_(max): 492.0 nm.

Example 134 2-[Isopropyl(methyl)amino]-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (134)

Yield: (70% of the theoretical value) MS: M/e=629.1; λ_(max): 492.0 nm.

Example 135 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-(dimethylamino)ethyl]oxime (127)

Yield: (90% of the theoretical value) MS: M/e=588.1; λ_(max): 492.0 nm.

Example 136 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propyl]oxime (136)

Yield: (85% of the theoretical value) MS: M/e=753.1; λ_(max): 492.0 nm.

Example 137 4′,9,9′-Trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(dimethylamino)propyl]oxime (137)

Yield: (70% of the theoretical value) MS: M/e=602.1; λ_(max): 492.0 nm.

Example 138 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydepyridine-2-yl-hydrazone (138)

Yield: (95% of the theoretical value) MS: M/e=627.0; λ_(max): 500.0 nm.

Example 139 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde [4-(trifluoromethyl)pyrimidine-2-yl]hydrazone (139)

Yield: (95% of the theoretical value) MS: M/e=696.0; λ_(max): 500.0 nm.

Example 140 (8S)-5-chloro-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]pyridyl-3-carbohydrazine (140)

Yield: (95% of the theoretical value) MS: M/e=655.0; λ_(max): 500.0 nm.

Example 141 (8S)-5-chloro-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]isonicotinohydrazide (141)

Yield: (95% of the theoretical value) MS: M/e=655.0; λ_(max): 500.0 nm.

Example 142 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-1,2,4-triazole-4-ylhydrazone (142)

Yield: (90% of the theoretical value) MS: M/e=602.0; λ_(max): 500.0 nm.

Example 143 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-4,5-dihydro-1H-imidazole-2-ylhydrazone (143)

Yield: (95% of the theoretical value) MS: M/e=618.0; λ_(max): 500.0 nm.

Example 144 (8S)-5-chloro-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-2-furohydrazide (144)

Yield: (95% of the theoretical value) MS: M/e=644.0; λ_(max): 500.0 nm.

Example 145 (8S)-5-chloro-4-amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-benzohydrazide (145)

Yield: (95% of the theoretical value) MS: M/e=669.0; λ_(max): 500.0 mm.

Example 146 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydethiosemicarbazone (146)

Yield: (95% of the theoretical value) MS: M/e=609.0; λ_(max):500.0 nm.

Example 147 (8S)-5-chloro-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]thiophene-2-carbohydrazide (147)

Yield: (95% of the theoretical value) MS: M/e=660.0; λ_(max): 500.0 nm.

Example 148 (8S)-5-chloro-2-(1H-indole-3-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (148)

Yield: (95% of the theoretical value) MS: M/e=707.1; λ_(max): 500.0 nm.

Example 149 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde(4-methylpiperazine-1-yl)hydrazone (149)

Yield: (95% of the theoretical value) MS: M/e=633.1; λ_(max): 500.0 nm.

Example 150 (8S)-5-chloro-2-oxo-2-{(2E)-2-[4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino}acetamide (150)

Yield: (95% of the theoretical value) MS: M/e=621.0; λ_(max): 500.0 nm.

Example 151 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (151)

Yield: (95% of the theoretical value) MS: M/e=665.3; λ_(max): 500.0 nm.

Example 152 (8S)-5-chloro-{(2E)-2-[4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino}acetonitrile (152)

Yield: (95% of the theoretical value) MS: M/e=617.1; λ_(max): 500.0 nm.

Example 153 (8S)-5-chloro-2-amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]benzohydrazide (153)

Yield: (95% of the theoretical value) MS: M/e=669.1; λ_(max): 500.0 nm.

Example 154 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-morpholine-4-yl-ethyl)oxime (154)

Yield: (95% of the theoretical value) MS: M/e=664.1; λ_(max): 500.0 nm.

Example 155 (8S)-5-chloro-(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazinecarboximidamide (155)

Yield: (95% of the theoretical value) MS: M/e=592.1; λ_(max): 500.0 nm.

Example 156 (8S)-5-chloro-2-(dimethylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (156)

Yield: (95% of the theoretical value) MS: M/e=635.1; λ_(max): 500.0 nm.

Example 157 (8S)-5-chloro-1-[2-oxo-2-((2E)-2-1[(8S)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino)ethyl]pyridinium chloride (157)

Yield: (95% of the theoretical value) MS: M/e=669.1; λ_(max): 500.0 nm.

Example 158 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-methyloxime (158)

Yield: (95% of the theoretical value) MS: M/e=565.0; λ_(max): 500.0 nm.

Example 159 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-benzyloxime (159)

Yield: (95% of the theoretical value) MS: M/e=641.1; λ_(max): 500.0 nm.

Example 160 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde oxime (160)

Yield: (95% of the theoretical value) MS: M/e=551.1; λ_(max): 500.0 nm.

Example 161 (8S)-5-chloro-1-O-(((1E)-[(8S)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]amino)-β-D-glucopyranose (161)

Yield: (95% of the theoretical value) MS: M/e=713.1; λ_(max): 500.0 nm.

Example 162 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-phenylsemicarbazone (162)

Yield: (95% of the theoretical value) MS: M/e=669.1; λ_(max): 500.0 nm.

Example 163 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydesemicarbazone (163)

Yield: (90% of the theoretical value) MS: M/e=593.0; λ_(max): 500.0 nm.

Example 164 (8S)-5-chloro-2-piperidino-4-yl-N′-[(1E)-[(8S)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (164)

Yield: (95% of the theoretical value) MS: M/e=675.1; λ_(max): 500.0 nm.

Example 165 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-chlorobenzyl)oxime (165)

Yield: (90% of the theoretical value) MS: M/e=675.0; λ_(max): 500.0 nm.

Example 166 (8S)-5-chloro-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]a-2-methyl-1,3-thiazole-4yl-carbohydrazide (166)

Yield: (95% of the theoretical value) MS: M/e=675.0; λ_(max): 500.0 nm.

Example 167 (8S)-5-chloro-2-(1H-imidazole-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (1647)

Yield: (90% of the theoretical value) MS: M/e=658.1; λ_(max): 500.0 nm.

Example 168 (8S)-5-chloro-2-(acetylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,81-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (164)

Yield: (95% of the theoretical value) MS: M/e=649.0; λ_(max): 500.0 nm.

Example 169 (8S)-5-chloro-2-(4-methylpiperazine-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (169)

Yield: (60% of the theoretical value) MS: M/e=690.1; λ_(max): 500.0 nm.

Example 170 (8S)-5-chloro-2-morpholine-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (170)

Yield: (60% of the theoretical value) MS: M/e=677.1; λ_(max): 500.0 nm.

Example 171 (8S)-5-chloro-2-(methylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (171)

Yield: (70% of the theoretical value) MS: M/e=621.1; λ_(max): 500.0 nm.

Example 172 (8S)-5-chloro-2-[isopropyl(methyl)amino]-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (172)

Yield: (95% of the theoretical value) MS: M/e=675.1; λ_(max): 500.0 nm.

Example 173 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-(dimethylamino)ethyl]-oxime (173)

Yield: (60% of the theoretical value) MS: M/e=622.0; λ_(max): 500.0 nm.

Example 174 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propyl]-oxime (174)

Yield: (90% of the theoretical value) MS: M/e=787.1; λ_(max): 500.0 nm.

Example 175 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(dimethylamino)propyl]oxime (175)

Yield: (75% of the theoretical value) MS: M/e=636.1; λ_(max): 500.0 nm.

Example 176 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydepyridine-2-yl-hydrazone (176)

Yield: (95% of the theoretical value) MS: M/e=670.9; λ_(max): 500.0 nm.

Example 177 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde [4-(trifluoromethyl)pyrimidine-2-yl]hydrazone (177)

Yield: (95% of the theoretical value) MS: M/e=739.9; λ_(max): 500.0 nm.

Example 178 (8S)-5-bromo-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]pyridyl-3-carbohydrazide (178)

Yield: (90% of the theoretical value) MS: M/e=699.0; λ_(max): 500.0 nm.

Example 179 (8S)-5-bromo-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]isonicotinohydrazide (179)

Yield: (90% of the theoretical value) MS: M/e=699.0; λ_(max): 500.0 nm.

Example 180 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-1,2,4-triazole-4-ylhydrazone (180)

Yield: (70% of the theoretical value) MS: M/e=645.9; λ_(max): 492.0 nm.

Example 181 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-4,5-dihydro-1H-imidazole-2-ylhydrazone (181)

Yield: (95% of the theoretical value) MS: M/e=662.0; λ_(max): 492.0 nm.

Example 182 (8S)-5-bromo-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-2-furohydrazide (182)

Yield: (95% of the theoretical value) MS: M/e=688.9; λ_(max): 492.0 nm.

Example 183 (8S)-5-bromo-4-amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]benzohydrazide (183)

Yield: (95% of the theoretical value) MS: M/e=713.0; λ_(max): 500.0 nm.

Example 184 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydethiosemicarbazone (184)

Yield: (95% of the theoretical value) MS: M/e=653.0; λ_(max): 500.0 nm.

Example 185 (8S)-5-bromo-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]thiophene-2-carbohydrazide (185)

Yield: (95% of the theoretical value) MS: M/e=704.0; λ_(max): 492.0 nm.

Example 186 (8S)-5-bromo-2-(1H-indole-3-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,81-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (186)

Yield: (95% of the theoretical value) MS: M/e=751.1; λ_(max): 500.0 nm.

Example 187 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde(4-methylpiperazine-1-yl)hydrazone (187)

Yield: (95% of the theoretical value) MS: M/e=677.1; λ_(max): 500.0 nm.

Example 188 (8S)-5-bromo-2-oxo-2-[(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino}acetamide (188)

Yield: (95% of the theoretical value) MS: M/e=665.0; λ_(max): 500.0 nm.

Example 189 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′,3′,5′,8′(2H)-pentone (189)

Yield: (95% of the theoretical value) MS: M/e=709.9; λ_(max): 492.0 nm.

Example 190 (8S)-5-bromo-((2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino)acetonitrile (190)

Yield: (95% of the theoretical value) MS: M/e=661.0; λ_(max): 500.0 nm.

Example 191 (8S)-5-bromo-2-amino-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]benzohydrazide (191)

Yield: (70% of the theoretical value) MS: M/e=713.0; λ_(max): 492.0 nm.

Example 192 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-morpholine-4-yl-ethyl)oxime (192)

Yield: (95% of the theoretical value) MS: M/e=708.0; λ_(max): 500.0 nm.

Example 193 (8S)-5-bromo-(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazinecarboximidamide (193)

Yield: (95% of the theoretical value) MS: M/e=636.0; λ_(max): 500.0 nm.

Example 194 (8S)-5-bromo-2-(dimethylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (194)

Yield: (95% of the theoretical value) MS: M/e=679.0; λ_(max): 500.0 nm.

Example 195 (8S)-5-bromo-1-[2-oxo-2-((2E)-2-{[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylenelhydrazino)ethyl]pyridinium chloride (195)

Yield: (95% of the theoretical value) MS: M/e=713.0; λ_(max): 500.0 nm.

Example 196 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-methyloxime (196)

Yield: (95% of the theoretical value) MS: M/e=609.0; λ_(max): 492.0 nm.

Example 197 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-O-benzyloxime (197)

Yield: (95% of the theoretical value) MS: M/e=685.0; λ_(max): 492.0 nm.

Example 198 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde oxime (198)

Yield: (95% of the theoretical value) MS: M/e=595.0; λ_(max): 492.0 nm.

Example 199 (8S)-5-bromo-1-O-(((1E)-[(8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene}amino)-β-D-glucopyranose (199)

Yield: (90% of the theoretical value) MS: M/e=757.0; λ_(max): 500.0 nm.

Example 200 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde-phenylsemicarbazone (200)

Yield: (90% of the theoretical value) MS: M/e=713.0; λ_(max; λ) _(max):500.0 nm.

Example 201 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehydesemicarbazone (201)

Yield: (90% of the theoretical value) MS: M/e=637.0; λ_(max): 492.0 nm.

Example 202 (8S)-5-bromo-2-piperidino-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (201)

Yield: (90% of the theoretical value) MS: M/e=719.0; λ_(max): 500.0 nm.

Example 203 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-chlorobenzyl)oxime (203)

Yield: (95% of the theoretical value) MS: M/e=718.0; λ_(max): 492.0 nm.

Example 204 (8S)-5-bromo-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]-2-methyl-1,3-thiazole-4yl-carbohydrazide (204)

Yield: (95% of the theoretical value) MS: M/e=718.9; λ_(max): 492.0 nm.

Example 205 (8S)-5-bromo-2-(1H-imidazole-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (205)

Yield: (95% of the theoretical value) MS: M/e=702.0; λ_(max): 500.0 nm.

Example 206 (8S)-5-bromo-2-(acetylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (206)

Yield: (95% of the theoretical value) MS: M/e=693.0; λ_(max): 492.0 nm.

Example 207 (8S)-5-bromo-2-(4-methylpiperazine-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (207)

Yield: (90% of the theoretical value) MS: M/e=734.1; λ_(max): 500.0 nm.

Example 208 (8S)-5-bromo-2-morpholine-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (208)

Yield: (95% of the theoretical value) MS: M/e=721.1; λ_(max): 500.0 nm.

Example 209 (8S)-5-bromo-2-(methylamino)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (209)

Yield: (95% of the theoretical value) MS: M/e=665.0; λ_(max): 500.0 nm.

Example 210 (8S)-5-bromo-2-[isopropyl(methyl)amino]-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (210)

Yield: (95% of the theoretical value) MS: M/e=707.0; λ_(max): 500.0 nm.

Example 211 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-(dimethylamino)ethyl]oxime (211)

Yield: (95% of the theoretical value) MS: M/e=666.0; λ_(max): 500.0 nm.

Example 212 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propyl]oxime (212)

Yield: (95% of the theoretical value) MS: M/e=831.0; λ_(max): 500.0 nm.

Example 213 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(dimethylamino)propyl]oxime (213)

Yield: (95% of the theoretical value) MS: M/e=680.0; λ_(max): 492.0 nm.

Example 214 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-isopropyloxime (214)

Yield: (95% of the theoretical value) MS: M/e=559.2; λ_(max): 500.0 nm.

Example 215 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-n-hexyloxime (215)

Yield: (99% of the theoretical value) MS: M/e=601.3; λ_(max): 500.0 nm.

Example 216 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-fluorobenzyl)oxime (216)

Yield: (99% of the theoretical value) MS: M/e=625.2; λ_(max): 500.0 nm.

Example 217 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-chlorobenzyl)oxime (217)

Yield: (99% of the theoretical value) MS: M/e=641.2; λ_(max): 500.0 nm.

Example 218 (8S)-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-fluorobenzyl)oxime (218)

Yield: (99% of the theoretical value) MS: M/e=625.3; λ_(max): 500.0 mm.

Example 219 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-isopropyloxime (219)

Yield: (80% of the theoretical value) MS: M/e=593.2; λ_(max): 500.0 nm.

Example 220 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-n-hexyloxime (220)

Yield: (90% of the theoretical value) MS: M/e=635.3; λ_(max): 500.0 nm.

Example 221 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-fluorobenzyl)oxime (221)

Yield: (85% of the theoretical value) MS: M/e=659.3; λ_(max): 500.0 nm.

Example 222 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-chlorobenzyl)oxime (222)

Yield: (80% of the theoretical value) MS: M/e=675.3; λ_(max): 500.0 nm.

Example 223 (8S)-5-chloro-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-fluorobenzyl)oxime (223)

Yield: (80% of the theoretical value) MS: M/e=659.3; λ_(max): 500.0 nm.

Example 224 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-isopropyloxime (224)

Yield: (90% of the theoretical value) MS: M/e=639.3; λ_(max): 492.0 nm.

Example 225 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-n-hexyloxime (225)

Yield: (95% of the theoretical value) MS: M/e=679.3; λ_(max): 492.0 um.

Example 226 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-fluorobenzyl)oxime (226)

Yield: (95% of the theoretical value) MS: M/e=703.3; λ_(max): 492.0 nm.

Example 227 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-chlorobenzyl)oxime (227)

Yield: (95% of the theoretical value) MS: M/e=719.3; λ_(max): 492.0 nm.

Example 228 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-fluorobenzyl)oxime (228)

Yield: (95% of the theoretical value) MS: M/e=705.3; λ_(max): 492.0 nm.

Example 229 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-isopropyloxime (229)

Yield: (99% of the theoretical value) MS: M/e=685.3; λ_(max):500.0 nm.

Example 230 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-n-hexyloxime (230)

Yield: (99% of the theoretical value) MS: M/e=727.4; λ_(max): 500.0 nm.

Example 231 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-fluorobenzyl)oxime (231)

Yield: (99% of the theoretical value) MS: M/e=751.3; λ_(max): 500.0 nm.

Example 232 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(4-chlorobenzyl)oxime (232)

Yield: (99% of the theoretical value) MS: M/e=767.3; λ_(max): 500.0 nm.

Example 233 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-fluorobenzyl)oxime (233)

Yield: (99% of the theoretical value) MS: M/e=751.3; λ_(max): 500.0 nm.

Example 234 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-benzyloxime (234)

Yield: (99% of the theoretical value) MS: M/e=733.3; λ_(max): 500.0 nm.

Example 235 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[2-morpholine-4-yl-ethyl)oxime (235)

Yield: (99% of the theoretical value) MS: M/e=756.3; λ_(max): 500.0 nm.

Example 236 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-methyloxime (236)

Yield: (95% of the theoretical value) MS: M/e=657.3; λ_(max): 492.0 nm.

Example 237 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-(3-chlorobenzyl)oxime (237)

Yield: (99% of the theoretical value) MS: M/e=767.3; λ_(max; λ) _(max):492.0 nm.

Example 238 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde O-[3-(4-(3-chlorophenyl)-piperazine-1-yl)propyl]oxime (238)

Yield: (99% of the theoretical value) MS: M/e=879.4; λ_(max): 500.0 nm.

Example 239 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-carbaldehyde oxime (239)

Yield: (99% of the theoretical value) MS: M/e=643.3; λ_(max): 492.0 nm.

Example 240 (8S)-5-iodo-2-(4-methylpiperazine-1-yl)-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (240)

Yield: (99% of the theoretical value) MS: M/e=782.3; λ_(max): 500.0 nm.

Example 241 (8S)-5-iodo-2-morpholine-4-yl-N′-[(1E)-(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]acetohydrazide (241)

Yield: (99% of the theoretical value) MS: M/e=782.3; λ_(max): 500.0 nm.

Example 242 (8S)-5-iodo-2-oxo-2-{(2E)-2-[(4′,9,9′-trihydroxy-6′-methoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl)methylene]hydrazino}acetamide (242)

Yield: (99% of the theoretical value) MS: M/e=713.3; λ_(max): 500.0 nm.

Example 243 (8S)-4′,9,9′-trihydroxy-6′-ethoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (243)

Five (5) mg (0.0095 mmol) fredericamycin (1) are suspended in 2.0 ml ethanol. Under N₂ atmosphere, 90 mg sodium acetate are added and boiled under reflux. After a few minutes, the suspension turns into a deep blue solution. After 24 h it is cooled, transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous, red powder is left.

Yield: 5.0 mg (97% of the theoretical value) MS=554 (M+H)+; λ_(max): 504.0 nm.

Example 244 (8S)-4′,9,9′-trihydroxy-6′-n-butoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (244)

Six (6) mg (0.0114 mmol) fredericamycin (1) are suspended in 3.0 ml n-butanol. Under N₂ atmosphere, 50 mg potassium acetate are added and heated to 100° C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 1 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 6.2 mg (96% of the theoretical value) MS=582 (M)+; λ_(max): 500.0 nm.

Example 245 (8S)-4′,9,9′-trihydroxy-6′-n-isopropyloxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (245)

Five (5) mg (0.0095 mmol) fredericamycin (1) are suspended in 3.0 ml n-propanol. Under N₂ atmosphere, 50 mg potassium acetate (anhydrous) are added and heated to 80° C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 48 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 3.7 mg (70% of the theoretical value) MS=568 (M+H)+; λ_(max): 500.0 nm.

Example 246 (8S)-4′,9,9′-trihydroxy-6′-(2-dimethylaminoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (246)

6.1 mg (0.01159 mmol) fredericamycin (1) are suspended in 3.5 ml N,N-Dimethylaminoethanol. Under N₂ atmosphere, 52 mg anhydrous potassium acetate are added and heated to 80° C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 1.5 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 2.4 mg (36% of the theoretical value); MS=597 (M+H)+; λ_(max): 504.0 nm.

Example 247 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-(2-dimethylaminoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (247)

Ten (10.0) mg (0.019 mmol) bromofredericamycin (14) are suspended in 3.0 ml ethanol. Under N₂ atmosphere, 50 mg anhydrous potassium acetate are added and heated to 80° C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 48 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 7.2 mg (71% of the theoretical value); MS=632/634 (M+H)+; λ_(max): 504.0 nm.

Example 248 (8S)-4′,9,9′-trihydroxy-6′-allyloxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (248)

9.6 mg (0.01824 mmol) fredericamycin (1) are suspended in 3.0 ml allyl alcohol. Under N₂ atmosphere, 58 mg anhydrous potassium acetate are added and heated to 70° C. After a few minutes, the suspension turns into a deep blue solution. The solution is left for 2.5 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 9.2 mg (91% of the theoretical value); MS=566 (M+H)+; λ_(max): 500.0 nm.

The compounds 249, 250, 251, 252, 253, 254, 255 were generated analogously to the instructions 244-248:

Example 249 (8S)-4′,9,9′-trihydroxy-6′-(2-hydroxyethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (249)

Yield: 5.2 mg (52% of the theoretical value); MS=569 (M)+; λ_(max): 499.0 nm.

Example 250 (8S)-4′,9,9′-trihydroxy-6′-benzyloxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (250)

Yield: 10.2 mg (99% of the theoretical value); MS=616 (M+H)+; λ_(max): 504.0 nm.

Example 251 (8S)-4′,9,9′-trihydroxy-6′-cyclopropylmethoxy-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (251)

Yield: 12.9 mg (99% of the theoretical value); MS=580 (M)+; λ_(max):500.0 nm.

Example 252 1-Desoxy-5-C-[(8R)-4′,9,9′-trihydroxy-6′-ethoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6′,7′,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]pentitol (252)

Yield: 2.0 mg (20% of the theoretical value); MS=622 (M+H)+; λ_(max): 499.0 nm.

Example 253 (8S)-4′,9,9′-trihydroxy-6′-(2-t-butoxycarbonylaminoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (253)

Yield: 12.9 mg (99% of the theoretical value); MS=669 (M)+; λ_(max): 500.0 mm.

Example 254 (8S)-4′,9,9′-trihydroxy-6′-(2-N,N-diisopropylaminoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (249)

Yield: 5.8 mg (48% of the theoretical value); MS=653 (M+H)+; λ_(max): 500.0 nm.

Example 255 1-Desoxy-5-C-[(8R)-4′,9,9′-trihydroxy-6′-ethoxy-1,1′,3′,5′,8′-pentaoxo-1,1′,2,3′,5′,6,7,8′-octahydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene)-3-yl]pentitol (255)

Yield: 5.5 mg (50% of the theoretical value); MS=594 (M+H)+; λ_(max): 500.0 nm.

Example 256 (8S)-4′,9,9′-trihydroxy-6′-(2-bromoethoxy)-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (256)

10.6 mg (0.02014 mmol) fredericamycin (1) are suspended in 2.0 ml bromoethanol. Under N₂ atmosphere, 150 mg anhydrous potassium acetate are added and heated to 120° C. After a few minutes, the suspension turns into a deep blue solution. After 12 hours, addition of another 150 mg potassium acetate. The solution is left for another 12 h at this temperature, and is then cooled. It is transferred onto water and shaken out with ethyl acetate (0.1% CF₃COOH). After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 11.5 mg (99% of the theoretical value); MS=632/634 (M+H)+; λ_(max): 499.0 nm.

Example 257 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-cyclopropylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopent[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (257)

Five (5.0) mg (7.5 μmol) 5-iodofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.64 mg (11.2 μmmol) cyclopropylamine, it is stirred at room temperature for 3 h. Excess cycloprolylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 5.1 mg (99%); MS=691.3 (M+H)+; λ_(max): 504.0 nm.

Example 258 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-n-butylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (258)

Five (5.0) mg (7.5 μmol) 5-iodofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.82 mg (11.2 μmmol) n-butylamine, it is stirred at room temperature for 20 h. Excess n-butylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 5.3 mg (99%); MS=707.3 (M+H)+; λ_(max): 504.0 nm.

Example 259 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-n-butylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (259)

Five (5.0) mg (8.1 μmol) 5-bromofredericamycin (15) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.89 mg (12.2 μmmol) n-butylamine, it is stirred at room temperature for 20 h. Excess n-butylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 5.3 mg (99%); MS=659.4/661.4 (M+H)+; λ_(max): 504.0 nm.

Example 260 (8S)-4′,9,9′-trihydroxy-6′-cyclopropylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (260)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 2.12 mg (37.2 μmmol) cyclopropylamine, it is stirred at room temperature for 2 h. Excess cyclopropylamine and DMF are removed at high vacuum. After drying and concentration, a chromatographically homogenous red powder is left.

Yield: 5.1 mg (99%); MS=565.4 (M+H)+; λ_(max): 510.0 nm.

Example 261 (8S)-4′,9,9′-trihydroxy-6′-anilino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (261)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.46 mg (37.2 μmmol) aniline and 37.2 μg stannous(IV)chloride (1.0 M in CH₂Cl₂), it is heated to 60° C. The reaction mixture is stirred for 24 h, and then excess diethanolaminomethyl polystyrene resin is added. Stir for 1 h. Exhaust off the resin and wash with DMF. The organic phase is concentrated at high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.5 mg (99%); MS=601.1 (M+H)+; λ_(max): 504.0 nm.

Example 262 (8S)-4′,9,9′-trihydroxy-6′-piperidino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (262)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.16 mg (37.2 μmmol) piperidine, it is stirred for 22 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.5 mg (99%); MS=593.4 (M+H)+; λ_(max): 504.0 nm.

Example 263 (8S)-4′,9,9′-trihydroxy-6′-dimethylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (263)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 1.67 mg (37.2 μmmol) dimethylamine (2M in MeOH), it is stirred for 4 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.5 mg (99%); MS=553.6 (M+H)+; λ_(max): 526.0 nm.

Example 264 (8S)-4′,9,9′-trihydroxy-6′-isopropylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (264)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 2.19 mg (37.2 μmmol) isopropylamine, it is stirred for 4 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.2 mg (99%); MS=567.3 (M+H)+; λ_(max): 504.0 nm.

Example 265 (8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (265)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.34 mg (11.1 μmmol) methylamine (2M in CH₃OH), it is stirred for 19 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.0 mg (99%); MS=539.2 (M+H)+; λ_(max): 504.0 nm.

Example 266 (8S)-5-iodo-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (266)

Five (5.0) mg (7.5 μmol) 5-iodofredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.28 mg (9.0 μmmol) methylamine (2M in CH₃OH), it is stirred for 2 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.0 mg (99%); MS=665.2 (M+H)+; λ_(max): 492.0 nm.

Example 267 (8S)-4′,9,9′-trihydroxy-6′-morpholino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (267)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 3.24 mg (37.2 μmmol) morpholine, it is stirred for 18 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.5 mg (99%); MS=595.5 (M+H)+; λ_(max): 518.0 nm.

Example 268 (8S)-4′,9,9′-trihydroxy-6′-amino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (268)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.67 mg (37.2 μmmol) ammonia (2M in EtOH), it is stirred for 24 h at room temperature. Excess ammonia and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 4.8 mg (99%); MS=525.4 (M+H)+; λ_(max): 504.0 nm.

Example 269 (8S)-4′,9,9′-trihydroxy-6′-pyrrolidino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (269)

Five (5.0) mg (9.3 μmol) fredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.99 mg (13.9 μmmol) pyrrolidine, it is stirred for 19 h at room temperature. Excess amine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.3 mg (99%); MS=579.2 (M+H)+; λ_(max): 554.0 nm.

Example 270 (8S)-5-bromo-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1,1′-3′,5′,8′(2H)-pentone (270)

Five (5.0) mg (8.1 μmol) 5-bromofredericamycin (1) are dissolved under argon in 1.0 ml anhydrous DMF. After addition of 0.70 mg (12.2 μmmol) cyclopropylamine, it is stirred for 5 h at room temperature. Excess cyclopropylamine and DMF are removed in high vacuum. A chromatographically homogenous red powder is left.

Yield: 5.0 mg (99%); MS=643.4/645.4 (M+H)+; λ_(max): 492.0 nmn.

Example 271 2-[Acetyl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopent[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (271)

79.5 mg (479 μmol) (2-oxo-propyl)-phosphonic acid dimethylester are dissolved under argon in 8 ml absolute pyridine, and 60.2 μl (479 μmol) 1,1,3,3-tetramethylguanidine are added at 0° C. After 5 minutes, 80.0 mg (159.7 μmol) fredericamycin aldehyde (4) is added at 0° C. After 2 hours, 100 ml 1 M hydrochloric acid are added, and the supernatant is sucked off from the precipitate. Dry under high vacuum.

Yield: 60.0 mg (69% of the theoretical value); M/e=542.2; λ_(max): 492.0 nm.

Example 272 2-[Bromoacetyl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (272)

Fifty (50.0) mg (92.4 μmol) acetyl fredericamycin are dissolved under argon in 5 ml absolute DMF, and then 36.9 mg (231.1 μmol) bromine as a 1 M bromine solution in DMF are added under exclusion of light. It is stirred for 23 h under exclusion of light, and then 100 ml water are added. The precipitate is sucked off and dried under high vacuum.

Yield: 57.0 mg (87% of the theoretical value) red powder; M/e=697.9/699.9/701.9; M+; λ_(max): 504.0 nm.

Example 273 2-[2-Amino-thiazole-4-yl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (273)

Twenty (20.0) mg (28.7 μmol) bromoacetyl fredericamycin (273) are dissolved under argon in 4 ml absolute DMF. At room temperature, first 3.3 mg (43.0 μmol) thiourea, and then 20 mg IR120H+ are added. After 2 hours, it is filtered off the resin, and added to 50 ml water. The precipitate is dried under high vacuum. Red powder.

Yield: 18.0 mg (93% of the theoretical value); M/e=676.1/678.1; (M+H); λ_(max): 492.0 nm.

Example 274 2-[2-Phenyl-thiazole-4-yl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopenta[g]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (274)

Five (5.0) mg (7.2 μmol) bromoacetyl fredericamycin (273) are dissolved under argon in 1 ml absolute DMF. At room temperature, first 1.5 mg (10.8 μmol) thiobenzamide, and then 5 mg IR120H+ are added. After 3.5 h, addition of hydrazinosulfonyl resin, and stirring for 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried under high vacuum. Red powder.

Yield: 3.0 mg (57% of the theoretical value); M/e=737.2/739.2; (M+H); λ_(max): 492.0 nm.

Example 275 2-[2-Acetylamino-thiazole-4-yl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)- penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (275)

Five (5.0) mg (7.2 μmol) bromoacetyl fredericamycin (273) are dissolved under argon in 1 ml absolute DMF. At room temperature, first 1.3 mg (10.8 μmol) acetylthiourea, and then 5 mg IR120H+ are added. After 22 h, addition of hydrazinosulfonyl resin, and stirring for 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried under high vacuum. Red powder.

Yield: 2.0 mg (39% of the theoretical value); M/e=718.3/720.4; (M+H); λ_(max): 492.0 nm.

Example 276 2-[2-Methyl-thiazole-4-yl]-3-[(8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-3-yl]ethene (276)

Five (5.0) mg (7.2 μmol) bromoacetyl fredericamycin (273) are dissolved under argon in 1 ml absolute DMF. At room temperature, first 0.81 mg (10.8 μmol) thioacetamide, and then 5 mg IR120H+ are added. After 2 h, addition of hydrazinosulfonyl resin, and stirring for 2 h. It is filtered off the resin, and added to 10 ml water. The precipitate is dried at high vacuum. Red powder.

Yield: 3.0 mg (62% of the theoretical value); M/e=675.2/677.2; (M+H); λ_(max): 492.0 nm.

Example 277 (8S)-4′,9,9′-trihydroxy-6′-methylamino-3-[(1E,3E)-penta-1,3-dienyl]-6,7-dihydrospiro[cyclopentag]isoquinoline-8,2′-cyclopenta[b]-naphthalene]-1-thio-1,1′-3′,5′,8′(2H)-tetrone-thiofredericamycin (277)

Ten (10.0) mg (18.5 μmol) fredericamycin (1) are dissolved under argon in 2 ml absolute pyridine. After addition of 20.5 mg (92.5 mmol) phosphorous-V-sulfide, it is heated for 12 h to 60° C. Addition of another 20.5 mg (92.5 mmol) phosphorous-V-sulfide. According to HPLC (acetonitrile/water CF₃COOH), the reaction was complete after 1 h. It is transferred onto water and shaken out with ethyl acetate. Dry and concentrate. Purple-red powder.

Yield: 5.0 mg (49% of the theoretical value); M/e=55.7; (M+H); λ_(max): 504.0 nm.

Example A Water Solubility of the Fredericamycin Derivatives

The water solubility of the various fredericamycin derivatives can be determined in a 0.9% NaCl solution with a pH of 7.

The compounds (22) and (3) dissolve very well. Compound (6) dissolves well, and compounds (2), (10), and (13) are soluble. Compounds (5), (7), (11) and (12) are sufficiently and markedly better soluble than fredericamycin (compound (1)). 

1. The compounds according to the general formula Ia or Ib:

wherein in each R1 means H, C₁-C₆ alkyl, cycloalkyl, or C₁-C₄ alkylcycloalkyl, R2 means H, C₁-C]₄ alkyl, C₂-C₁₄ alkenyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, C₂-C₄ alkenylheteroaryl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=I, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o; Y=independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, and SH SR21), (CH₂)_(r)CH₂NHCOR21, (CH₂)_(r)CH₂OCOR21, (CH₂)_(r)CH₂NHCSR21, (CH₂)_(r)CH₂S(O)nR21, with n=0, 1, 2, (CH₂)_(r)CH₂SCOR21, (CH₂)_(r)CH₂OSO₂—R21, (CH₂)_(r)CHO, (CH₂)_(r)CH═NOH, (CH₂)_(r)CH(OH)R21, —(CH₂)_(r)CH═NOR21, (CH₂)_(r)CH═NOCOR21, (CH₂)_(r)CH═NOCH₂CONR2 I R22, (CH₂)_(r)CH═NOCH(CH₃)CONR21R22, (CH₂)_(r)CH═NOC(CH₃)₂CONR21R22, (CH₂)_(r)CH═N—NHCO—R23, (CH₂)_(r)CH═N—NHC(O)NH—R23, (CH₂)_(r)CH═N—NHC(S)NH—R23, (CH₂)_(r)CH═N—NHC(NH)NH—R23, (CH₂)_(r)CH═N—NHC(NH)—R23, (CH₂)_(r)CH═N—NHCO—CH₂NHCOR21, (CH₂)_(r)CH═N—OCH₂NHCOR21, (CH₂)_(r)CH═N—NHCS—R23, (CH₂)_(r)CH═CR24R25 (trans or cis), (CH₂)_(r)COOH, (CH₂)_(r)COOR21, (CH₂)_(r)CONR21R22, —(CH₂)_(r)CH═NR21, (CH₂)_(r)CH═N—NR21R22,

, and the (CH₂)_(r)-chain elongated residue (CH₂)_(r)CH═N—N—(C₃NX′R211R212R213R214) (with X′=NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl), —(CH₂)_(r)CH═N—NHSO₂ aryl, or —(CH₂)_(r)CH═N—NHSO₂ heteroaryl, with r=0, 1, 2, 3, 4, 5, R21, R22 are independently H, C₁-C₁₄ alkyl, C₁-C₁₄ alkanoyl, C₁-C₆ alkylhydroxy, C₁-C₆ alkoxy, C₁-C₆ alkylamino, C₁-C₆ alkylamino-C₁-C₆ alkyl, C₁-C₆ alkylamino-di-C₁-C₆-alkyl, cycloalkyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, aryloyl, C₁-C₄ alkylaryl, heteroaryl, heteroaryloyl, C₁-C₄ alkylheteroaryl, cycloalkanoyl, C₁-C₄ alkanoylcycloalkyl, heterocycloalkanoyl, C₁-C₄ alkanoylheterocycloalkyl, C₁-C₄ alkanoylaryl, C₁-C₄ alkanoylheteroaryl, mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereoisomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), or R21 and R22, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S, R23 independently of R21, has the same meanings as R21, or CH₂-pyridinium salts, CH₂-tri- C₁-C₆ alkylammonium salts, CONH₂, CSNH₂, CN, or CH₂CN, R24 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21, R25 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21, R24, R25 together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S, R3 means H, F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH_(3-m)hal_(m) (with hal=Cl, F, and m=1, 2, 3), or OCOR31, R31, R32 are independently C₁-C₆ alkyl, or R31 and R32, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S, R5 means H, C₁-C₂₀ alkyl, cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₁₀ alkinyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o; Y=independently selected from the group consisting of halogen, OH, OR51, NH₂, NHR51, NR51R52, SH, SR21), (CH₂), CH₂NHCOR51, (CH₂)_(s)CH₂NHCSR51, (CH₂)_(s)CH₂S(O)_(n)R51, with n=0, 1, 2, (CH₂)_(s)CH₂SCOR51, (CH₂)_(s)CH₂OCOR51, (CH₂)_(s)CH₂OSO₂—R51, (CH₂)_(s)CH(OH)R51, (CH₂)_(s)COOH, (CH₂)_(s)COOR51, (CH₂)_(s)CONR51R52, with s=0, 1, 2, 3, 4, 5, mono- and di-sugar residues linked through a C atom which would carry an OH residue in the sugar, wherein the sugars are independently selected from the group consisting of glucuronic acid and its stereo isomers at all optical atoms, aldopentoses, aldohexoses, including their desoxy compounds (as e.g. glucose, desoxyglucose, ribose, desoxyribose), with the mono-sugar residues such as aldopentoses, aldohexoses, including their desoxy compounds with R51, R52 which are capable of independently adopting the meaning of R21, R22, R4, R6, R7 independently mean H, C₁-C₆ alkyl, CO—R41, R41 independently from R21, has the same meanings as R21, X means O, S, NH, N—R8, wherein R8 independently from R5 may adopt the same meaning as R5, or R5 and R8, together with the N, form a ring with 4, 5, 6, 7, or 8 members, which may optionally contain still another heteroatom selected from the group N, O, and S, or X—R5 may together be H, Y means O, S, NR9, wherein R9 may be H or C₁-C₆ alkyl, as well their stereoisomers, tautomers, and their physiologically tolerable salts or inclusion compounds, wherein the residues for Formula Ia may not concomitantly adopt the following meaning, except in case of cyclodextrin inclusion compounds: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, Y: O, and for Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X—R5 being methoxy, Y: O.
 2. The compounds according to claim 1, wherein Formula Ia or Ib adopts the stereochemistry of Formula IIa or IIb


3. The compounds of Formula Ia, Ib, IIa, IIb according to claim 2, wherein R2 has a water solubility that is at least two times higher compared to R2 being CH═CH—CH═CH—CH₃, with all other residues being maintained.
 4. The compounds according to claim 1, wherein R3 means F, Cl, Br, I, OH, OR31, NO₂, NH₂, NHR31, NR31R32, NHCHO, NHCOR31, NHCOCF₃, CH_(3-m)hal_(m) (with hal=Cl, F, and m=1, 2, 3), or OCOR31.
 5. The compounds according to claim 1, wherein R3 means (CH₂)_(r)CHO, (CH₂)_(r)CH═NOH, —(CH₂)_(r)CH═NOR21, (CH₂)_(r)CH═NOCOR21, (CH₂)_(r)CH═NOCH₂CONR21R22, (CH₂)_(r)CH═NOCH(CH₃)CONR21R22, (CH₂)_(r)CH═NOC(CH₃)₂CONR21R22, (CH₂)_(r)CH═N—NHCO—R23, (CH₂)_(r)CH═N—NHC(O)NH—R23, (CH₂)_(r)CH═N—NHC(S)NH—R23, (CH₂)_(r)CH═N—NHC(NH)NH—R23, (CH₂)_(r)CH═N—NHC(NH)—R23, (CH₂)_(r)CH═N—NHCO—CH₂NHCOR21, (CH₂)_(r)CH═N—O—CH₂NHCOR21, (CH₂)_(r)CH═N—NHCS—R23, (CH₂)_(r)CH═CR24R25 (trans or cis), (CH₂)_(r)CH═NR21, (CH₂)_(r)CH═N—NR21R22,

and the (CH₂)_(r)-chain elongated residue (CH₂)_(r)CH═N—N—(C₃NX′R211R212R213R214) (with X′=NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl), (CH₂)_(r)CH═N—NHSO₂ aryl, (CH₂)_(r)CH═N—NHSO₂ heteroaryl, with r=0, 1, 2, 3, 4,
 5. 6. The compounds according to claim 1, wherein X means N or S, or X—R5 is OH.
 7. The compounds according to claim 1, wherein R1 means H, C₁-C₅ alkyl, cycloalkyl, R2 means C₁-C₅ alkyl, C₁-C₄ alkylaryl, C₂-C₅ alkenyl, heteroaryl, C₁-C₄ alkylheteroaryl, CHF₂, CF₃, polyol side chain, CH₂Y (Y=F, Cl, Br, I), CH₂NH₂, CH₂NR21R22, CH₂NHCOR23, CH₂NHCSR23, CH₂SH, CH₂S(O)_(n)R21, with n=0, 1, 2, CH₂SCOR21, CH₂OH, CH₂OR21, CH₂OSO₂—R21, CHO, CH(OR21)₂, CH(SR21)₂, CN, CH═NOH, CH═NOR21, CH═NOCOR21, CH═N—NHCO—R32, CH═CR24, R25 (trans or cis), COOH, COOR21, CONR21R22, —CH═NR21, —CH═N—NR21R22,

(with X′=NR215, O, S, and R211, R212, R213, R214, R215 being independently H or C₁-C₆ alkyl), —CH═N—NHSO₂ aryl, —CH═N—NHSO₂ heteroaryl, or CH═N—NHCO—R23, R21, R22 independently mean C₁-C₆ alkyl, cycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, or C₁-C₄ alkylheteroaryl, R23 independently of R21, has the same meanings as R21, or CH₂-pyridinium salts, or CH₂-tri-C₁-C₆ alkylammonium salts, R24 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH. COOR21, CONR21R22, NH₂, or NHCOR21, R25 independently of R21, has the same meanings as R21, or H, CN, COCH₃, COOH, COOR21, CONR21R22, NH₂, or NHCOR21, R24, R25 together mean C₄-C₈ cycloalkyl, R3 means F, Cl, Br, I, NO₂, NH₂, or NHCOR31, R31 independently means C₁-C₆ alkyl, R5 means H, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, C₁-C₆ alkenyl, C₁-C₆ alkinyl, C₁-C₄ alkylcycloalkyl, heterocycloalkyl, C₁-C₄ alkylheterocycloalkyl, aryl, C₁-C₄ alkylaryl, heteroaryl, C₁-C₄ alkylheteroaryl, C_(m)H_(2m+o−p)Y_(p) (with m=1 to 6, for o=1, p=1 to 2 m+o; for m=2 to 6, o=−1, p=1 to 2 m+o; for m=4 to 6, o=−2, p=1 to 2 m+o; Y=independently selected from the group consisting of halogen, OH, OR21, NH₂, NHR21, NR21R22, SH, SR21), hydroxyalkyl with one or more OH groups, R4, R6, R7 independently mean H, C₁-C₅ alkyl, or CO—R41, R41 independently from R21, has the same meanings as R21, X means O, S. NH, or N—R8, Y means O, or S.
 8. The compounds according to claim 1 in the form of inclusion compounds with cyclodextrin.
 9. Drugs containing compounds according to claim 1, a carrier and adjuvants.
 10. Drugs according to claim 9 in combination with further agents for tumor treatment.
 11. A preparation of drugs for tumor treatment which comprises using compounds according to claim
 1. 12. A preparation of drugs for treatment of parasites which comprises using the compounds according to claim 1, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X—R5 being methoxy.
 13. A preparation of drugs for immunosuppression which comprises the compounds according to claim 1, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X—R5 being methoxy.
 14. A preparation of drugs for treatment of neurodermitis which comprises using compounds according to claim 1, or compounds in which the following meanings can be concomitantly adopted in case of Formula Ia: R1: H, C₁-C₆ alkyl, R2: C₁-C₆ alkyl, C₂-C₆ alkenyl, R3: H, R4 and R6 identical, and independently H, C₁-C₆ alkyl, CO—R41, with R41 being C₁-C₆ alkyl, aryl, and R7 being H, C₁-C₆ alkyl, and in case of Formula Ib: R1: H, R2: pentyl, 1-pentenyl, 3-pentenyl, 1,3-pentdienyl, R3: H, R4 and R6 being H, and X—R5 being methoxy. 